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Abstract	
	
Background	
Xpert	MTB/RIF	(Xpert)	is	a	rapid,	automated,	onsite	nucleic	acid	amplification	test	for	
tuberculosis	(TB).		It	is	effective	for	the	diagnosis	of	pulmonary	TB	but	there	is	limited	
evidence	for	its	usefulness	in	extrapulmonary	TB,	particularly	musculoskeletal	TB.		
	
Aims	and	hypothesis	
The	aim	of	this	thesis	was	to	investigate	the	diagnostic	accuracy	of	Xpert	for	musculoskeletal	
TB	and	for	rifampicin	resistance	against	a	gold	standard	of	culture	or	histology.			Site	of	
disease,	HIV	status,	and	age	of	patients,	and	accuracy	in	spinal	compared	to	extraspinal	TB	
were	investigated	as	secondary	objectives.		
The	overarching	hypothesis	was	that	Xpert	is	more	accurate	and	would	provide	results	faster	
than	the	gold	standard	for	musculoskeletal	TB,	and	that	it	would	have	a	higher	yield	in	HIV	
infected	patients,	adult	patients,	and	patients	with	spinal	disease.	
	
Methods	
Prospective	studies	of	patients	with	suspected	musculoskeletal	TB,	at	the	tertiary	care	
hospitals	Groote	Schuur	and	Red	Cross	Children’s	Hospital	in	Cape	Town,	South	Africa,	were	
undertaken	from	June	2013	to	March	2015.	The	diagnostic	accuracy	of	Xpert	was	compared	
to	culture	or	histopathology.		
	
Findings	
206	biopsies	of	201	patients	older	than	13	years	of	age	(23%	HIV	positive)	were	analysed.	
The	sensitivity	and	specificity	of	Xpert	was	92.3%	and	99.1%	respectively.		Xpert	detected	8	
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cases	more	than	culture	(p	=	0.069)	and	positive	results	were	available	17	days	earlier	
(<0.001).	The	sensitivity	of	Xpert	in	HIV	positive	patients	was	96.9%	(31/32)	versus	89.6%	
(43/48)	in	HIV	negative	patients	(p=0.225).	The	sensitivity	of	Xpert	for	spinal	biopsies	was	
93.8%	(95%	CI	86.0-97.9)	with	specificity	of	97.6%	(95%	CI	87.4	–	99.9),	compared	to	extra-
spinal	biopsies	with	a	sensitivity	of	81.8%	(95%	CI	48.2	–	99.7,	p=0.164)	and	specificity	of	
100%	(95%	CI	95.1	–	100%,	p=0.186).				
109	osteoarticular	samples	of	children	12	years	of	age	or	younger,	with	a	median	age	of	5.6	
years	(IQR	2.2	–	8.7)	were	analysed.	Xpert	provided	a	sensitivity	of	73.9%	(95%	CI	51.6-89.8)	
with	a	specificity	of	100%	(95%	CI	95.7	-	100)	and	was	available	at	a	mean	of	0.8	days	(0.46-
1.4)	compared	to	21	days	(19	–	30)	for	culture	(p	<0.001).			
All	rifampicin	resistant	cases	were	correctly	diagnosed.	A	trend	towards	higher	sensitivity	in	
spinal	tissue	as	well	as	HIV	infected	patients	was	observed.		This	study	also	provides	
evidence	that	Xpert	has	a	lower	sensitivity	in	children	than	in	adults,	yet,	still	detects	more	
cases	of	paediatric	musculoskeletal	TB	and	is	faster	than	culture.	Histology	was	a	useful	test	
for	the	diagnosis	of	musculoskeletal	TB,	especially	in	children,	and	should	be	used	alongside	
Xpert	to	provide	the	highest	yield	possible	to	detect	TB.	
	
Conclusion:		
These	first	large	studies	on	the	accuracy	of	Xpert	for	musculoskeletal	TB	provide	evidence	
for	the	usefulness	of	Xpert	in	the	diagnosis	of	spinal	TB,	extraspinal	TB,	in	HIV	positive	
patients,	and	in	childhood	musculoskeletal	TB.	Based	on	these	results,	Xpert	should	be	
recommended	as	the	initial	test	for	diagnosis	as	it	is	more	sensitive	and	faster	than	the	gold	
standard	of	liquid	culture.	
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Abbreviations	
AIDS	 	 	 	 Acquired	immune	deficiency	syndrome	
CI	 	 	 	 Confidence	Interval	
DNA	 	 	 	 Deoxyribonucleic	Acid	
ESR	 	 	 	 Erythrocyte	Sedimentation	Rate	
GeneXpert	 	 	 Xpert	MTB/RIF,	Xpert	
HIV	 	 	 	 Human	Immunodeficiency	Virus	
LPA	 	 	 	 Line	Probe	Assay	
MDR	 	 	 	 Multi-drug	resistance	
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Chapter	1	
Introduction	
	
This	chapter	has	the	following	contents:	
1. Context	and	literature	review	
1.1. Review	of	the	epidemiology	of	musculoskeletal	TB	
1.2. Diagnostic	tests	for	musculoskeletal	TB	
1.3. Xpert	MTB/RIF	assay	and	its	diagnostic	accuracy	for	musculoskeletal	TB	
1.4. Reporting	on	diagnostic	accuracy		
2. Summary	and	problem	statement	
3. Aims		
4. Hypotheses	
1. Context	and	Literature	review	
1.1. Epidemiology	of	musculoskeletal	tuberculosis	
Incidence	of	TB	
Worldwide,	9	million	new	TB	cases	with	3.5%	multidrug	resistant	TB	(MDR-TB)	and	1.5	
million	TB	related	deaths	are	reported	annually.	Of	the	new	TB	cases	25%	are	reported	in	
Africa	and	more	than	500	cases	per	100.000	inhabitants	in	South	Africa.	Extrapulmonary	
disease	accounts	for	10%	to	42%	of	TB	cases,	of	which	around	10-25%	have	musculoskeletal	
TB	(Figure	1).	1-3	
	 12	
	In	the	Western	Cape,	the	incidence	of	pulmonary	TB	is	even	higher	with	1400	per	100	000	
inhabitants.4	
	
Figure	1.	Estimated	TB	incidence	rates	in	2013.2	
Epidemiology	of	extrapulmonary	TB	
In	the	1960s	extrapulmonary	TB	(EPTB)	comprised	7.6%	of	all	TB	cases	in	developed	
countries.	This	has	since	increased	to	20–40	%	as	reported	in	recent	studies5-7	with	about	
20%	in	children.		Although	EPTB	is	usually	not	infectious	it	can	cause	death	if	undiagnosed	or	
untreated.8,	9	Transmission	risk	of	patients	with	EPTB	is	given	when	concurrent	pulmonary	TB	
is	present,	which	is	the	case	in	between	7%	and	20%	of	EPTB.7,	10,	11		
Epidemiologic	studies	in	industrialized	countries	as	well	as	resource-constrained	areas	found	
that	young	patients,	females,	and	persons	of	African	or	Asian	origin	had	a	higher	risk	for	
EPTB.10-12	HIV	co-infection	led	to	an	increased	rate	of	EPTB	and	in	such	cases	also	to	a	higher	
mortality.	13,	14	
Epidemiology	of	musculoskeletal	TB	
Extrapulmonary	TB	accounts	for	10%	to	42%	of	TB	cases,	of	which	around	10-25%	have	
musculoskeletal	TB.	1-3	The	estimated	global	prevalence	of	joint	and	bone	TB	is	
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approximately	19	million	to	38	million	cases.	15	The	most	affected	site	of	infection	is	the	
spine	(50-69%),	followed	by	hip,	knee,	and	ankle/foot	(10-13%	each).12		
Musculoskeletal	TB	in	children	
Childhood	TB	is	estimated	to	account	for	15-20%	(pulmonary	and	extrapulmonary	TB)	of	the	
total	caseload	in	African	countries2;	3%	of	these	have	musculoskeletal	TB,	but	
epidemiological	data	regarding	musculoskeletal	TB	in	children	is	very	rare.16,	17	At	Red	Cross	
Children’s	Hospital	in	Cape	Town,	the	largest	children’s	hospital	in	sub-Saharan	Africa,	
approximately	20	children	under	the	age	of	12	years	are	treated	for	musculoskeletal	TB	each	
year	(60%	spinal	TB,	20%	in	knee,	16%	in	hip	and	less	then	5%	TB	of	the	ankle	or	upper	
limb).18	
HIV/TB	co-infection	and	multidrug	resistant	(MDR)	TB	
An	estimated	1.1	million	(13%)	of	the	9	million	people	who	developed	TB	in	2013	were	HIV-
positive.2	The	prevalence	of	HIV	co-infection	among	TB	patients	is	highest	in	the	African	
region.2	Among	the	high	TB/HIV	burden	countries,	this	ranged	from	7%	in	Mali	to	74%	in	
Lesotho	and	Swaziland	(Figure	2).2			
	
Figure	2.	Estimated	HIV	prevalence	in	new	and	relapse	TB	cases	in	2013.2	
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Similar	to	HIV/AIDS,	MDR-TB	remains	an	unsolved	problem	as	the	WHO	estimates	3.5%	of	
new	cases	and	20.5%	of	previously	treated	cases	to	be	multidrug	resistant.		Although	South	
Africa	has	one	of	the	world’s	highest	TB	and	MDR-TB	rates1,	the	epidemiology	for	EPTB	and	
especially	musculoskeletal	TB	remains	largely	unknown.		We	estimate	that	MDR-TB	has	a	
prevalence	of	5%	in	musculoskeletal	TB	in	our	population19	making	a	correct	diagnosis	on	
tissue	biopsy	imperative	to	identify	resistance	and	initiate	optimal	treatment.			
1.2. Diagnostic	tests	for	musculoskeletal	TB	
Conventional	Tests	
For	musculoskeletal	TB,	clinical	and	radiological	diagnosis	has	poor	accuracy,	as	it	is	a	great	
mimicker	of	various	other	skeletal	conditions.20	But	accurate	and	timely	diagnosis	is	essential	
to	 prevent	 joint	 destruction,	 growth	 arrest,	 and	 contractures	 in	 large	 joints	 as	 well	 as	
deformity	 with	 neurological	 compromise	 in	 spinal	 disease,	 which	 may	 lead	 to	 lifelong	
morbidity	 and	 disability.21-25	 The	 current	 gold	 standard	 to	 test	 for	 osteoarticular	 TB	 is	
mycobacterial	 culture	 and	histology.26	 For	 pulmonary	 samples,	 a	meta-analysis	 reported	 a	
time	to	detection	of	22	(smear	positive)	to	34	(smear	negative)	days	in	Loewenstein-Jensen	
medium	 and	 12	 (smear	 positive)	 to	 18	 days	 (smear	 negative)	 in	 radiometric	 Bactec	 460	
medium.	The	sensitivity	and	specificity	in	detecting	pulmonary	TB	with	BACTEC	460	systems	
is	87.7	and	89.7%,	respectively.27	However,	joint	biopsy	samples	usually	contain	only	a	small	
number	 of	 bacteria,	 making	 culture	 and	 staining	 for	 acid-fast	 bacilli	 challenging.15,	 28	 The	
sensitivity	of	TB	culture	(Loewenstein-Jensen	medium)	compared	to	a	composite	reference	
standard	for	childhood	musculoskeletal	TB	is	approximately	73%	(70%	in	hips,	71%	in	knees,	
70%	 in	 ankles,	 75%	 in	 feet	 and	 ankles).18,	 24,	 29,	 30	 Similar	 sensitivities	 are	 reported	 for	
musculoskeletal	TB	in	adults31	with	up	to	90%	for	spinal	TB.32	These	conventional	tests	require	
experienced	microbiologists	and	extensive	laboratory	setup	and	their	shortcomings	demand	
a	new,	fast	and	accurate	test,	which	is	readily	available	and	affordable.	
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Non-automated	Nucleic	Acid	Amplification	Tests	(NAAT)	in	musculoskeletal	TB	
Most	nucleic	acid	amplification	tests	for	TB	use	polymerase	chain	reaction	(PCR).		This	
method	uses	high	temperature	to	split	double	stranded	DNA	into	single	strands.	DNA	
polymerase	is	then	used	to	synthesize	a	complementary	DNA	strand	and	form	double	
stranded	DNA	again	with	added	oligonucleotides.	This	process	can	be	repeated	multiple	
times	to	amplify	specific	DNA	sequences.	For	musculoskeletal	TB,	various	studies	have	
reported	on	the	sensitivity	of	non-automated	NAATs	ranging	from	61%	to	83%	in	extra-
spinal	osteoarticular	samples33,34,35	and	94%	in	spinal	samples.36	One	study	also	reported	a	
higher	sensitivity	in	spinal	biopsies	(90%)	compared	to	extraspinal	biopsies	(63%)	with	
culture	as	a	reference	standard.37	In	Children,	non-automated	NAATs	of	synovial	joint	
biopsies	have	a	reported	sensitivity	of	only	40%	when	compared	to	culture	or	histology.23		
1.3. Xpert	MTB/RIF	(Xpert)	
The	 Foundation	 for	 Innovative	 New	 Diagnostics	 (FIND)	 has	 collaborated	 with	 an	 industry	
partner	(Cepheid,	Sunnyvale,	CA)	to	develop	Xpert®	MTB/RIF.		Further	funding	was	provided	
by	 the	 US	 National	 Institutes	 of	 Health.	 The	 laboratory	 of	 Professor	 David	 Alland	 at	 the	
University	 of	 Medicine	 and	 Dentistry	 in	 New	 Jersey	 provided	 technical	 support.	 	 Xpert	
MTB/RIF	(Xpert)	carries	a	registered	trademark	and	is	manufactured	by	Cepheid.	
The	Xpert	assay	is	a	cartridge	based,	automated,	in	vitro	form	of	a	NAAT	(Figure	3).	The	system	
uses	 single-use	 cartridges	 to	 eliminate	 cross-contamination	 between	 samples.	 Its	 primers	
amplify	part	of	the	rpoB	gene	containing	an	81	base	pair	core	region.	Mutations	in	this	region,	
which	have	previously	been	isolated	and	conserved,	are	associated	with	rifampicin	resistance	
and	can	be	detected	by	means	of	five	molecular	beacons	(A-E)	each	labelled	with	a	different	
fluorophore.			
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Being	automatic,	It	is	therefore	not	only	very	fast	but	also	obviates	the	need	for	a	labour-	and	
cost-intensive	 laboratory	 set-up	 necessary	 for	 non-automated	 NAATs.	 It	 is	 therefore	 an	
attractive	 test	 for	 the	 resource	 constrained	 environments	 of	 countries	 with	 a	 high	 TB	
burden.38		
	
Figure	3.	Steps	using	the	Xpert	assay.39		
Advantages	and	Disadvantages	of	Xpert	
Xpert	has	the	advantage	of	requiring	much	smaller	quantities	of	M.	tuberculosis	to	
demonstrate	infection.		Its	detection	limit	of	130	mycobacteria	per	millilitre	in	various	
clinical	samples	increases	the	diagnostic	predictability	in	extra-pulmonary	tuberculosis	even	
with	samples	with	only	a	few	bacteria	present.	40,41	A	disadvantage	of	Xpert	is	that	it	will	lead	
to	positive	results	even	if	the	pathogens	are	non-viable	and	so	remains	positive	for	long	
periods	after	treatment.42	In	these	cases	active	TB	will	have	to	be	confirmed	clinically	and	by	
means	of	various	imaging	modalities.		The	automated	sample	processing	in	Xpert	has	a	step	
which	removes	DNA	of	non-intact	cells	to	limit	false	positivity.	Yet,	in	one	of	7	patients	with	
previous	TB	retreated	for	new	onset	pulmonary	TB,	Xpert	is	found	to	be	false	positive.43	This	
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is	a	higher	false	positive	rate	than	for	new	cases.		Fewer	years	since	TB	treatment	
completion	and	a	negative	chest	X-Ray	are	clinical	features	associated	with	false	positivity.	43		
Costs	for	Xpert	MTB/RIF	
The	concessional	price	for	a	four-module	Xpert	instrument	is	approximately	17	000	US	
dollars,	with	a	cartridge	price	of	9.98	US	dollars).		The	cartridge	price	for	the	private	market	
varies	widely	between	40	and	155	US	dollars.44		Xpert	also	generates	hidden	costs	as	it	needs	
a	stable	electricity	supply,	constant	temperature	and	needs	to	be	calibrated	yearly.	In	
comparison,	the	automated	BACTEC	MGIT	960	by	Diagnostic	Systems,	Sparts	MD	(Franklin,	
Lakes,	NJ,	USA)	with	an	annual	capacity	of	8300	tubes	is	38	950	US	Dollars.		A	fee	of	5	000	US	
Dollars	will	cover	3	years	of	Instrument	service.	A	test	tube	is	1.95	US	Dollars.		These	prices	
have	been	negotiated	for	South	African	public	sector	hospitals	by	the	Foundation	for	
Innovative	New	Diagnostics	(FIND).	Additional	costs	which	need	to	be	considered	are	
infrastructure,	human	resources,	as	well	as	delivery	costs	and	pathways	for	reporting.	
Assessing	the	costs	to	prevent	each	disability-associated	life-year	(defined	as	number	of	
years	lost	due	to	a	disease,	disability	or	early	death),	modelling	studies	have	found	that	in	
countries	of	high	disease	burden,	Xpert	is	cost	effective,	either	in	addition	to	or	as	a	
replacement	test	of	conventional	testing	methods. 45-49	A	high	rate	of	empirical	TB	treatment	
practiced	in	low	and	middle	income	countries	with	a	high	disease	burden	could	undermine	
this	estimated	effect	of	Xpert.50-52	In	a	recent	study	cost	per	screened	subject	was	13.09	US	
Dollars	and	the	cost	per	notified	TB	case	was	90.7	US	Dollars	when	using	Xpert. 53		This	cost	
could	be	reduced	with	automated	chest	radiography	analysing	for	TB	via	computer	software	
and	screening	cases	prior	to	Xpert	testing.	
Accuracy	of	Xpert	in	pulmonary	TB	of	adults	and	children	
Xpert	 has	 been	 validated	 for	 pulmonary	 TB	 in	 adults	 and	 in	 children	 but	 not	 for	
musculoskeletal	TB.		For	adult	pulmonary	TB,	Xpert	MTB/RIF	(Xpert)	has	shown	to	have	the	
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potential	to	become	a	faster	alternative	to	the	current	reference	standard,	which	is	sputum	
microscopy	and	culture.42,	54,	55	 In	a	recent	meta-analysis	 it	had	a	sensitivity	of	90%,	and	an	
accuracy	to	detect	rifampicin	resistance	of	94%	for	pulmonary	TB.56	Another	meta-analysis	of	
studies	on	the	diagnostic	accuracy	of	Xpert	in	adults	showed,	that	Xpert	is	more	sensitive	and	
specific	compared	with	microscopy	and	culture).57	When	comparing	respiratory	samples	of	
HIV-negative	to	HIV-positive	patients	a	slight	increase	in	sensitivity	has	also	been	shown	for	
HIV-infected	cases	[86%	(95%	CI	76-92%)	compared	to	79%	(95%	CI	70-86%)	HIV-uninfected].				
For	 childhood	 PTB	 at	 Red	 Cross	 Children’s	 Hospital,	 the	 sensitivity	 of	 Xpert	 on	 repeated	
induced	sputum	specimens	compared	to	liquid	culture	is	approximately	70%58	and	in	a	recent	
meta-analysis59	 the	 pooled	 sensitivity	 of	 a	 single	 Xpert	 was	 62%.	 Another	meta-analysis60	
reported	that	Xpert	had	moderate	sensitivity	and	high	specificity	of	65%	(95%	CI:	61	-	69%)	
and	 99%	 (95%	 CI:	 98	 -	 99%),	 respectively	 for	 childhood	 pulmonary	 TB.	 Sensitivity	 and	
specificity	for	paediatric	rifampicin	resistance	were	94.0%	(95%	CI:	80.0	-	93.0%)	and	99.0%	
(95%	CI:	95.0	-	98.0%),	respectively.		
Similar	 findings	 have	 recently	 been	 confirmed	 by	 a	 large	 multicentre	 trial61	 reporting	 a	
sensitivity	of	68%	(95%	CI,	50%-82%)	and	specificity	of	100%	(95%	CI,	97%-100%)	in	children	
with	suspected	pulmonary	TB	when	compared	with	culture.	Xpert	detected	1.7	times	more	
culture-confirmed	cases	 than	smear	microscopy	with	a	 similar	 time	 to	detection.	 	Another	
recent	multicentre	 trial	 assessed	Xpert	 in	 alternative	 specimens	 in	HIV-Infected	 children.62	
Sensitivities	 in	all,	standard,	and	alternative	samples	were	79.3%	(95%	CI	60.3-92.0),	72.4%	
(95%	CI,	52.8-87.3),	and	75.9%	(95%	CI,	56.5-89.7),	 respectively.	Specificities	were	≥97.5%.	
Xpert	combined	on	nasopharyngeal	aspirate	and	stool	had	sensitivities	of	75.9%	(95%	CI,	56.5-
89.7)	and	75.0%	(95%	CI,	47.6-92.7),	respectively.	
Accuracy	of	Xpert	in	extrapulmonary	tissue	samples	
The	 number	 of	 bacteria	 in	 extrapulmonary	 specimens	 is	 often	 lower	 than	 in	 pulmonary	
specimens,	influencing	the	detection	rate	and	making	diagnosis	more	challenging.		There	are	
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few	diagnostic	accuracy	studies	of	extrapulmonary	samples	since	extrapulmonary	TB	is	less	
common	and	invasive	procedures	have	to	be	performed	to	obtain	tissue.		In	one	meta-analysis	
for	 adult	 tissue	 samples	 of	 various	 origins,	 the	 sensitivity	 varied	widely	 between	42%	and	
100%.39	Another	meta-analysis	on	 studies	 reporting	diagnostic	accuracy	of	Xpert	 in	mostly	
extra-osseous	extrapulmonary	samples	 found	a	pooled	sensitivity	of	81.2%	(95%	CI,	67.7	–	
89.0%)	and	specificity	of	98.1%	(95%	CI,	87.0	–	99.8%).63	
There	are	no	studies	on	the	diagnostic	accuracy	of	Xpert	of	extrapulmonary	TB	in	children.		
Rifampicin	resistance	testing	with	Xpert	
Rifampicin	 resistance	 occurs	 most	 commonly	 via	 mutation	 of	 the	 rpoB	 gene	 encoding	 a	
subunit	of	 the	bacterial	RNA	polymerase,	which	 is	 the	binding	site	 for	 the	antibiotic.64	The	
Xpert	does	not	detect	resistance	to	any	other	antibiotics	(multidrug	resistance)	used	to	treat	
TB	and	therefore	culture	is	still	recommended.	A	line	probe	assay	(LPA),	is	a	DNA	strip	test,	
such	 as	 GenoType®	MTBDRplus	 or	 GenoType®	Mycobacterium	 CM	 lineprobe	 assays	 (Hain	
Lifescience,	Nehren,	Germany).		It	is	used	to	detect	multidrug	resistance.		The	WHO	therefore	
recommends	the	use	of	molecular	LPA	for	the	rapid	diagnosis	of	MDR-TB	in	high	TB-burden,	
low-income	settings.64	
Current	 evidence	 supports	 the	 accuracy	 of	 Xpert	 to	 detect	 resistance	 to	 rifampicin.	 	 Its	
sensitivity	and	specificity	in	adults	for	pulmonary	TB	is	high	(95%	and	98%	respectively).	39	In	
a	meta-analysis,	data	on	resistance	testing	 in	tissue	was	available	for	566	samples	from	13	
studies.	 	 Xpert	 missed	 2	 of	 41	 rifampicin	 resistant	 samples.	 The	 average	 prevalence	 of	
rifampicin	resistance	was	5.4%.39	
Accuracy	of	Xpert	in	musculoskeletal	TB	
Data	on	Xpert	of	bone	and	joint	tissue	samples	are	very	limited	(Table	1).	One	study	on	29	
adults	with	spinal	disease	reported	Xpert	to	have	a	sensitivity	of	72%	in	HIV	negative	and	
82%	in	HIV	positive	patients,	but	this	was	compared	to	a	clinical	reference	standard.65	
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Another	study66	compared	Xpert	in	60	adult	orthopaedic	fluid	samples	with	culture	and	
found	a	sensitivity	of	63.6%	(14/22).		Large	studies	of	the	accuracy	of	Xpert	in	children	or	
adults	are	not	available	for	extrapulmonary	tissue	samples,	let	alone	musculoskeletal	
samples.			
Study	 Sens	(%)	
Spec	
(%)	
PPV	
(%)	
NPV	
(%)	
Sens	RIF	
(%/N)	
Reference	
Standard	 Design	 Age	 N	 Type	
Monni	
2012	65	 72		(82	in	HIV)	 100	 100	 67	 not	done	 Clinico-radiologic	signs	 prospective	 adults	 29	 tissue	
Gu	
2015	66	 63.6	(14/22)	 not	given	 not	given	 not	given	 100	(6/6)	 culture	or	histology	 prospective	 adults	 60	 pus	
	
Table	1.	Current	evidence	on	diagnostic	accuracy	of	Xpert	in	musculoskeletal	samples.		
Sens	=	Sensitivity,	Spec	=	Specificity,	PPV	=	positive	predictive	value,	NPV	=	negative	predictive	value,	
Sens	RIF	=	sensitivity	of	Xpert	to	detect	Rifampcin	resistance,	N	=	number,	Type	=	Type	of	specimen	
collected.	
2.	Summary	and	problem	statement	
	
There	is	a	lack	of	data	on	an	accurate,	rapid	diagnostic	test	in	musculoskeletal	TB.	A	new,	
rapid	diagnostic	method,	the	Xpert	assay,	is	an	automated	sample	preparation	and	real-time	
PCR	instrument.		For	pulmonary	TB,	this	test	has	shown	to	have	high	accuracy	and	perform	
faster	than	the	current	reference	standard,	which	is	sputum	microscopy	and	culture.		
Currently	no	large	studies	have	assessed	the	accuracy	of	Xpert	in	adult	and	childhood	
musculoskeletal	TB	or	in	HIV-infected	compared	to	uninfected	patients	with	musculoskeletal	
disease.		
3.	Aims	
	
The	overall	aim	was	to	assess	the	diagnostic	accuracy	of	Xpert	to	detect	musculoskeletal	TB	
and	rifampicin	resistance	in	tissue	of	bone	or	joints.		As	the	diagnostic	yield	of	conventional	
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tests	might	be	influenced	by	site	of	disease,	HIV	status	and	age	of	the	patients,	specific	
objectives	included	assessing	the	accuracy	of	Xpert	in	Children	(0-12	years	of	age),	HIV	
infected	patients,	as	well	as	spinal	and	extraspinal	TB.	
4. Hypotheses		4.1 Xpert	has	been	established	as	the	first	line	test	for	pulmonary	TB	and	has	been	proven	
to	be	faster	and	more	accurate	than	culture.		We	therefore	hypothesized,	that	for	
osteoarticular	TB,	Xpert	will	outperform	the	current	gold	standard	(culture	and	
histology)	in	accuracy	and	time	to	diagnosis	and	will	have	potential	to	become	the	first	
line	test.	4.2 Xpert	is	accurate	for	detection	of	rifampicin	resistance	in	pulmonary	and	
extrapulmonary	TB.		We	therefore	hypothesized	it	would	detect	rifampicin	resistance	in	
musculoskeletal	specimens	with	high	accuracy.		4.3 Affected	tissue	in	children	and	extraspinal	TB	contain	paucibacillary	disease	compared	to	
that	in	adults	or	spinal	TB.		We	therefore	hypothesized	that	Xpert	would	be	more	
accurate	in	adults	than	in	children,	as	well	as	in	spinal	tuberculosis	compared	to	
extraspinal	tuberculosis.			4.4 Xpert	has	a	higher	accuracy	in	pulmonary	samples	of	HIV-infected	patients	compared	to	
HIV	negative	patients.		We	therefore	hypothesized	that	Xpert	would	have	a	higher	
accuracy	in	HIV-infected	patients	with	musculoskeletal	TB	compared	to	HIV	negative	
patients.		
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Chapter	2		
Study	outline	and	methodology	
Study	Design	
This	was	a	prospective	study	on	the	diagnostic	accuracy	of	Xpert®	MTB/RIF	(Xpert)	assay	
(Cepheid,	Sunnyvale,	CA)	in	patients	with	suspected	musculoskeletal	TB	in	a	TB	and	HIV	
endemic	setting.		The	diagnostic	performance	and	time	to	availability	of	the	results	of	the	
Xpert	assay	were	compared	to	standard	tissue	microscopy	and	culture.	
Recruitment	
All	patients	presenting	with	features	suspicious	of	musculoskeletal	TB	(Table	1)	to	Groote	
Schuur	Hospital	and	Red	Cross	Children’s	Hospital	in	Cape	Town	from	June	2013	to	March	
2015	were	included.	Biopsies	were	collected	by	a	specialized	orthopaedic	service.	Spinal	TB	
was	managed	by	a	subspecialist	spinal	service.		Paediatric	patients	were	managed	by	a	
subspecialised	paediatric	orthopaedic	team.	
Inclusion	Criteria	
Patients	were	included	in	the	study	with	the	following	criteria:	
1. Patients	presented	with	suspected	musculoskeletal	TB	(Table	1).	
2. A	tissue	biopsy	was	performed	as	part	of	the	routine	clinical	workup	
3. A	valid	Xpert	and	TB	culture	were	obtained	
4. Age	of	paediatric	group:	age	0-12	years,	recruited	at	Red	Cross	Children’s	Hospital	
5. Age	of	adult	group:	older	than	12	years	of	age,	recruited	at	Groote	Schuur	Hospital	
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Clinical	Red	Flags	 Radiological	Red	Flags	
• History	of	chronic	pain	for	more	than	3	
months	
• Constitutional	symptoms:	low	grade	fever,	
night	sweats,	loss	of	appetite,	weight	loss	
• Chronic	cough	
• Elevated	ESR	
• History	of	Tuberculosis	contact	
• Gibbus	
• Neurological	deficit	
• Positive	Mantoux	test	
• Immune	compromise/HIV	
• Loss	of	anterior	vertebral	height	
• Paravertebral	shadow	on	XRs	
• Shadow	of	a	psoas	abscess	
• Adjacent	Vertebral	endplate	changes	with	
preserved	disc	height	
• Changes	on	Chest	X-Ray	suspicious	of	TB	
• Paravertebral	abscess	on	MRI	
	
	
Table	1:	Clinical	and	radiological	red	flags	on	which	the	suspected	diagnosis	of	TB	was	made.	
Exclusion	Criteria	
Patients	were	excluded	if	one	of	the	following	was	present:	
1. Invalid	Xpert	assay	or	TB	culture	
2. Tissue	biopsy	not	indicated	(prior	diagnosis	of	TB)		
3. No	consent	given.	
Research	Procedures	
Index	Test	–	Xpert	MTB/RIF	(Xpert)	
Specimens	 were	 submitted	 in	 sterile	 saline	 in	 duplicate	 to	 the	 mycobacterial	 culture	
laboratory.	 The	 first	 specimen	was	 processed	 for	 onsite	 Xpert®	MTB/RIF	 testing	 (Cepheid,	
Sunnyvale,	CA).		
Xpert	SR	lysis	buffer	was	added	in	a	1:3	ratio	and	the	specimen	was	vortexed	initially	and	again	
after	10	minutes.	Two	millilitres	of	 the	mixture	were	processed	automatically	according	to	
Xpert	 protocols	 the	 result	 was	 read	 after	 approximately	 90	 min.	 A	 trained	 laboratory	
technician	performed	the	test	and	was	blinded	to	the	results	of	the	reference	test.	
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Reference	Standard	
The	reference	standard	was	liquid	culture	or	histology.	The	cultures	were	processed	with	the	
automated	BACTEC	MGIT	960	by	Diagnostic	Systems,	Sparts	MD	(Franklin,	Lakes,	NJ,	USA).		A	
Ziehl-Nielson	(ZN)	stain	and	a	haematoxylin	and	eosin	(HE)	stain	were	done	in	the	
microbiology	and	histopathology	laboratory	respectively.			
Quantification	of	acid-fast	bacilli	was	read	according	to	the	specifications	from	the	Centres	
for	Disease	Control	and	Prevention.	The	isolate	was	assessed	for	multidrug	resistant	TB	
(MDR-TB)	using	the	GenoType®	MTBDRplus	or	GenoType®	Mycobacterium	CM	lineprobe	
assays	(Hain	Lifescience,	Nehren,	Germany).		The	accuracy	of	Xpert	to	detect	rifampicin	
resistance	was	assessed.		“MDR-TB”	was	defined	as	resistance	to	isoniazid	and	rifampicin,	
with	or	without	resistance	to	other	first-line	drugs.2	
A	trained	pathologist	experienced	in	diagnosing	TB	reviewed	the	histopathology	slides.	
Histological	features	of	TB	were	caseous	necrosis,	epitheloid	cell	granulomas	or	Langhans	
giant	cells.		Clinical	data,	imaging,	as	well	as	the	Xpert	test	results	were	available	to	the	
pathologist.		
Sample	collection	
The	sample	collection	for	the	Xpert®	MTB/RIF	assay	(Cepheid,	Sunnyvale,	CA),	culture	and	
histopathology	was	done	as	part	of	the	routine	clinical	management	and	according	to	local	
guidelines	for	the	management	of	patients	with	suspected	musculoskeletal	TB.		There	was	
no	additional	surgery	or	surgical	insult	to	the	patient	to	obtain	tissue	or	perform	research	
related	biopsies.	Tissue	was	taken	from	the	predetermined	area	of	disease	and	then	divided	
into	equal	parts	to	be	processed	for	the	index	and	reference	tests.		If	indicated	clinically,	
repeat	biopsies	were	performed	on	the	basis	of	an	unclear	diagnosis	or	as	part	of	a	protocol	
of	multiple	washouts	to	control	sepsis.	Musculoskeletal	tissue	samples	were	collected	
surgically	in	an	operating	room	under	sterile	conditions	from	radiographically	
predetermined	areas	of	disease.		Tissue	samples	were	taken	from	synovium	in	articular	
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biopsies	and	bone	in	extra-articular	biopsies.		Spinal	tissue	biopsies	were	performed	by	a	
subspecialised	spine	team.		Extraspinal	lesions	were	biopsied	by	a	specialised	orthopaedic	
team.		Paediatric	patients	were	managed	and	biopsied	by	a	subspecialist	paediatric	
orthopaedic	team.		All	extraspinal	biopsies	were	carried	out	as	open	procedure	targeting	the	
area	of	suspected	disease.	For	spinal	TB,	percutaneous	biopsies	were	carried	out	by	a	
transpedicular	approach	in	the	thoracic	and	a	paraspinal	approach	in	the	lumbar	spine.		An	
open	biopsy	was	performed	when	debridement	of	granulomata	and	drainage	of	
paravertebral	abscesses	or	stabilization	of	the	spinal	column	was	found	to	be	necessary.	
Indications	included	instability	of	the	spinal	column,	acute	deterioration	of	neurology,	a	
large	paravertebral	abscess,	and	airway	compromise	in	lesions	of	the	cervical	spine.		
Abscesses	were	drained	through	a	costotransversectomy	in	the	thoracic	spine	and	through	
an	anterolateral	retroperitoneal	approach	in	the	lumbar	spine.		A	thoracotomy	was	carried	
out	when	stabilization	of	the	anterior	column	of	the	thoracic	spine	was	necessary.		The	
Smith-Robinson	approach	was	used	for	lesions	of	the	cervical	spine.	
Biopsy	material	included	pus	swabs	and/or	tissue	biopsies	from	diseased	bone	or	soft	tissue.	
All	samples	were	subjected	to	Xpert	assay	and	histopathological	examination	as	well	as	
microbiological	testing.	
Definitions	
For	the	first	publication	on	spinal	TB	(chapter	3),	‘definite	TB’	was	defined	as	a	positive	
Mycobacterium	Tuberculosis	culture.		In	patients	with	negative	cultures,	‘probable	TB’	was	
assumed	if	histology	along	with	clinical	and	radiological	findings	(Table	1)	were	suggestive	of	
TB	and	if	patients	improved	on	TB	therapy.	‘NOT	TB’	was	assumed	in	cases	who	tested	
negative	for	culture	and	histology	and	who	improved	without	TB	treatment.		
For	the	publications	in	chapter	4	and	5	“confirmed	TB”	was	defined	as	a	positive	M	
tuberculosis	culture	or	positive	histology.		A	negative	culture	and	histology	with	
improvement	of	symptoms	without	TB	treatment	after	at	least	a	month	of	follow	up	was	
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considered	‘NOT	TB’.	Improvement	was	assessed	by	means	of	signs	of	sclerosis	on	X-Ray,	
clinical	improvement	such	as	weight	gain	and	diminished	pain	as	well	as	decreasing	
Erythrocyte	Sedimentation	Rate	(ESR).	The	diagnostic	accuracy	of	Xpert	was	compared	to	
liquid	culture	or	histology	(confirmed	TB	or	probable	TB).			
Medical	treatment	was	provided	for	confirmed	or	probable	TB	cases	according	to	the	
protocol	of	the	local	infectious	disease	guidelines	and	was	given	for	9	months.		Patients	
underwent	follow-up	evaluations	every	3	months.		
Statistical	Analysis	
The	sensitivity,	specificity	and	predictive	values	of	Xpert	with	95%	confidence	intervals	(95%	
CI)	were	calculated	using	TB	culture	or	histology	as	reference	standard.	
The	data	was	analysed	as	per	sample	using	STATA	13	statistical	software	(STATA	
Corporation,	College	Station,	TX	USA).	Descriptive	statistics	were	used	to	characterise	the	
study	population,	normally	distributed	continuous	data	were	summarized	by	mean	and	95%	
confidence	interval,	non-normally	distributed	continuous	data	by	median	and	interquartile	
range.	Categorical	data	were	summarized	as	proportions	with	95%	confidence	intervals.	
Statistical	tests	included	two-sample	test	of	proportions,	chi	squared	test,	Kruskal	Wallis	test	
and	Wilcoxon	rank-sum	test.	All	statistical	tests	were	two-sided	at	α	=	0·05.	
Ethics		
The	procedure	was	explained	to	patients	and	/	or	caregivers	as	well	as	its	risks	and	benefits.		
A	patient	or	caregiver	information	sheet	was	provided.	Informed	written	consent	was	taken	
in	all	cases	undergoing	surgery.		The	study	was	approved	by	the	human	research	ethics	
committee	of	the	Faculty	of	Health	Science,	University	of	Cape	Town	(Appendix:	HREC	REF	
206/2013).	
Description	of	risks	and	benefits	
Patients	received	usual	treatment	according	to	local	and	South	African	guidelines,	which	
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conform	to	internationally	accepted	standards	of	care	for	musculoskeletal	TB.			
Data	safety	and	Reimbursement	
All	patients’	names	and	folder	numbers	were	removed	from	the	data	stream.	This	study	
adhered	to	the	Declaration	of	Helsinki	2013.		There	was	no	reimbursement.	
Reporting	
As	part	of	the	EQUATOR	toolkit	for	authors,	the	Standards	for	the	Reporting	of	Diagnostic	
accuracy	studies	(STARD)	were	used	to	give	a	structured	guidance	for	the	design	and	
reporting	of	this	diagnostic	accuracy	study.67	
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Chapter	3	
Xpert	MTB/RIF	for	spinal	Tuberculosis	-	An	accurate	and	rapid	diagnostic	test.	
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Abstract	
The	lack	of	an	accurate,	rapid	diagnostic	test	for	M.	tuberculosis	(TB)	is	a	major	challenge	in	
spinal	TB.		Xpert	MTB/RIF	(Xpert),	a	new,	rapid	molecular	diagnostic	test	is	recommended	as	
the	first	line	investigation	for	suspected	pulmonary	TB	in	areas	of	high	HIV	prevalence	or	drug	
resistance,	yet	it	has	not	been	validated	for	the	diagnosis	of	musculoskeletal	TB.	The	aim	of	
this	study	was	to	assess	the	accuracy	of	Xpert	for	spinal	TB.		A	prospective	clinical	study	of	69	
consecutive	adults	hospitalised	with	suspected	spinal	TB	was	conducted	at	a	tertiary	hospital	
in	an	area	with	one	of	the	highest	TB	incidence	and	prevalence	worldwide.		The	Xpert	was	
performed	on	tissue	samples	of	the	enrolled	patients	and	the	diagnostic	accuracy	was	
compared	to	a	reference	standard	of	tissue	in	liquid	culture.		Seventy-one	spine	samples	
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from	69	patients	(2	re-biopsies)	were	included	in	the	study.		The	Xpert	test	showed	a	high	
sensitivity	of	95.6	%	and	specificity	of	96.2%	in	spinal	TB.	The	test	results	were	available	on	
day	2	for	the	Xpert	test,	compared	to	day	35	for	cultures.		All	multi-	drug	resistant	TB	(MDR-
TB)	cases	were	diagnosed	accurately	with	the	Xpert	test.		The	MDR-TB	rate	was	5.8%.		
	
Introduction	
Accurate	diagnosis	of	musculoskeletal	tuberculosis	(TB)	is	essential	to	enable	timely	and	
effective	treatment.	Rapid	availability	of	test	results	and	initiation	of	treatment	is	important	
to	halt	disease	progression	and	prevent	further	morbidity.		In	spinal	TB,	diagnostic	delay	can	
lead	to	devastating	neurological	compromise	and	irreversible	disability.		
Xpert®	MTB/RIF	(Xpert)	assay	(Cepheid,	Sunnyvale,	CA),	an	automated	Polymerase	Chain	
Reaction	(PCR)	diagnostic	test	that	simultaneously	detects	TB	and	Rifampicin	resistance,	has	
recently	become	available.	The	World	Health	Organization	(WHO)	has	endorsed	this	for	use	
in	patients	with	suspected	pulmonary	TB	in	areas	of	high	HIV	or	drug	resistance.		For	
pulmonary	TB,	this	test	method	has	often	been	quoted	with	similar	sensitivity	and	specificity	
to	conventional	testing	methods	such	as	TB	culture.1-4	
A	recent	meta-analysis	of	the	Cochrane	Infectious	Diseases	Group	has	analysed	18	studies	
with	7816	patients.		The	Xpert	was	carried	out	on	sputum	in	suspected	pulmonary	TB	and	a	
sensitivity	of	approximately	90%	with	a	false	negative	rate	of	2%	was	reported.		The	
sensitivity	for	rifampicin	resistance	was	94%.5	
According	to	the	WHO	Global	Tuberculosis	Report	2013	the	Xpert	test	will	be	made	available	
universally	in	future	with	massive	roll	out	programs	by	the	WHO.6	However,	there	is	no	data	
on	its	accuracy	for	diagnosis	of	musculoskeletal	TB.			
The	aim	of	this	study	was	to	investigate	the	accuracy	of	the	Xpert	assay	compared	to	the	
gold	standard	of	culture	and	microscopy.	
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Methods	
The	methods	are	stated	in	chapter	2.	
	
Results	
Seventy-one	spine	samples	from	69	patients	(2	re-biopsies)	were	included	in	the	study,	31	
were	males	(44.9%).		Their	median	age	was	40	years	(IQR	27	-	60).		Twenty-two	(31.9%)	of	
the	69	patients	were	HIV	positive,	37	patients	were	HIV	negative	(53.6%),	in	10	patients	HIV	
testing	was	not	done.			
Overall	36	(52.2%)	patients	were	classified	as	definite	TB	(culture	positive),	8	(11.6%)	as	
probable	TB	(histology	positive	but	culture	negative)	and	25	(36.2%)	as	not	TB	(culture	and	
histology	negative)	(Table	2).	A	total	of	44	patients	had	a	positive	Xpert	result.	Xpert	was	
positive	in	97.2%	of	the	patients	in	the	“definite	TB”	group,	100.0%	(8)	in	the	“probable	TB”	
group	and	4.0%	(N=1)	in	the	“not	TB”	group.	(Table	2)	
Table	3	shows	the	per	sample	analysis	of	all	cases	with	either	culture	positive	(‘definite	TB’)	
or	histology	positive	(‘probable	TB’)	samples,	the	sensitivity	of	Xpert	PCR	test	was	95.6%	
(95%	CI	[84.9	–	99.5]),	specificity	96.2%	([80.4	–	99.9]),	positive	predictive	value	97.7%	(95%	
CI	[88.0	–	99.9])	and	negative	predictive	value	92.6%	(95%	CI	[75.7	–	99.1]).		There	were	2	
false	negative	and	1	false	positive	Xpert	sample	in	this	analysis.	
A	secondary	analysis	was	done	to	compare	Xpert	to	only	culture	positive	samples	(definite	
TB)	as	the	reference	standard	(Table	3).			Culture	detected	37	TB	cases	and	histology	
detected	a	further	8	cases.		With	Xpert	the	yield	of	TB	detection	compared	to	cultures	alone	
increased	by	(8	of	37	cases)	21.6%.		This	demonstrates	that	the	8	cases	which	where	only	
detected	on	histology	(probable	TB)	could	likely	be	false	negative	TB	cultures.			The	
sensitivity	of	Xpert	for	this	secondary	analysis	was	92.6%,	detecting	25	of	27	cases	(95%	CI	
[75.7	–	98.9]	with	a	specificity	of	79.55%	(35/44);	95%	CI	[64.7	–	90.2],	a	positive	predictive	
	 31	
value	of	73.5%	(25/34);	95%	CI	[55.6-	87.1]	and	negative	predictive	value	of	94.6%	(35/37);	
95%	CI	[81.8	–	99.2].			
In	the	Xpert	test,	the	results	were	available	at	a	maximum	of	2	days	compared	to	a	median	
of	35	(IQR	[15-43])	days	for	culture.	
In	4	patients	rifampicin-resistant	TB	was	evident	on	the	Xpert	test	(5.8%)	and	possible	multi-
drug	resistant	TB	(MDR-TB)	was	therefore	suspected.		All	4	patients	could	be	started	on	the	
correct	MDR-TB	treatment	regimen	one	day	after	the	biopsy.		In	3	of	the	4	patients	MDR-TB	
was	confirmed	with	sensitivity	testing	for	Rifampicin	and	Isoniazid	once	the	culture	was	
available.		In	one	of	the	4	Xpert	samples	with	Rifampicin	resistance,	the	TB	culture	was	
negative	and	therefore	MDR-TB	may	have	been	missed	without	the	Xpert	test.				
Conversely,	in	another	Xpert	test	sample,	Isoniazid	mono-resistance	was	evident	only	on	
culture	as	the	Xpert	tests	solely	for	Rifampicin	resistance	
	
Discussion	
Clinical	and	radiological	diagnosis	of	musculoskeletal	TB	notoriously	has	poor	accuracy,	as	TB	
is	 a	 great	 mimicker	 of	 various	 other	 skeletal	 conditions.8	 	 	 Often	 the	 TB	 culture	 is	 time	
consuming	(on	average	6-8	weeks)	and	one	often	relies	on	histological	evidence.		This	requires	
experienced	microbiologists	and	close	communication	with	the	treating	physician	but	most	
importantly	demands	a	test,	which	is	accurate,	readily	available,	rapid	and	cheap.			
With	the	advent	of	PCR	methods	to	test	for	TB,	various	studies	have	reported	on	the	
sensitivity	of	non-automated	PCR	tests	ranging	from	61%	to	83%.9-14	The	PCR	method	has	
the	advantage	of	requiring	much	smaller	quantities	of	M.	tuberculosis	to	demonstrate	
infections	and	leads	to	a	rapid	diagnosis	through	amplification	of	nucleic	acid	of	the	
pathogen.		Its	detection	limit	of	130	colony-forming	units	(CFU)	per	millilitre	(versus	10.000	
CFU/ml	in	cultures)	in	various	clinical	samples	increased	the	diagnostic	predictability	in	
extra-pulmonary	tuberculosis	even	with	samples	with	only	a	few	bacteria	present.15,16	
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In	this	study,	the	sensitivity	of	the	Xpert	test	was	95.6%	(95%	CI	[84.9	–	99.5]),	the	specificity	
was	96.2%	([80.4	–	99.9]),	the	positive	predictive	value	was	97.7%	(95%	CI	[88.0	–	99.9])	and	
negative	predictive	value	was	92.6%	(95%	CI	[75.7	–	99.1]).	
Four	MDR-TB,	5.8%	of	all	patients,	were	accurately	diagnosed	with	the	Xpert	test.		In	one	of	
these	patients	culture	results	were	false	negative,	reported	at	43	days	post	biopsy.		These	
patients	would	have	been	discharged	into	the	community	without	adequate	treatment	for	
43	days,	and	in	one	case	without	treatment	at	all,	highlighting	the	benefit	of	the	Xpert	test.	
Another	major	benefit	of	the	Xpert	test	is	its	rapid	time	for	test	results	to	be	available.		In	
our	study,	In	the	Xpert	test,	the	results	were	available	at	a	maximum	of	2	days	compared	to	
median	of	35	(IQR	[15-43])	days	for	culture.		The	automated	process	of	the	Xpert	device	
takes	only	about	90	minutes	to	completion	and	most	of	the	time	lost	was	due	to	the	
infrastructure	required	to	run	the	test.		Compared	to	other	PCR	testing	methods,	the	
automated,	cartridge	based	test	obviates	extensive	laboratory	support.		This	makes	it	a	tool	
which	can	be	moved	closer	to	smaller	hospitals	and	clinics	cutting	down	long	transport	times	
and	complex	logistics	often	present	in	countries	with	a	high	TB	burden.	
One	group	has	found	no	difference	in	time	compared	to	conventional	testing	methods	when	
the	Xpert	device	was	not	onsite.	Time	delays	in	transport	made	it	similar	to	their	reference	
standard	of	cultures	and	histology	and	they	found	no	added	benefit.17	
One	of	the	disadvantages	of	PCR	testing	is	that	in	contrast	to	TB	culture,	PCR	testing	will	lead	
to	positive	results	even	if	the	pathogens	are	non-viable.1	In	these	cases	active	TB	will	have	to	
be	confirmed	clinically	and	by	means	of	various	imaging	modalities.			
Another	concern	for	the	Xpert	method	is	that	it	tests	drug	resistance	only	for	Rifampicin	
therefore	a	mono-resistance	for	Isoniazid	can	only	be	detected	with	another	PCR	testing	
method	(Hain).		In	our	series,	one	case	of	Isoniazid	mono-resistance	was	discovered.		
Though,	according	to	current	treatment	guidelines	Isoniazid	mono-resistance	does	not	
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require	any	change	to	the	conventional	TB	regimen	for	patients	without	Isoniazid	mono-
resistance.		Thus	there	was	no	clinical	impact.18		
	
Conclusion	
The	Xpert	shows	a	high	sensitivity	of	95.6	%	and	specificity	of	96.2%	in	spinal	TB.		The	yield	
of	TB	detection	with	Xpert	compared	to	cultures	alone	increased	by	21.6%.		The	test	results	
were	available	on	day	2	for	the	Xpert	test,	compared	to	day	35	for	cultures.		All	MDR-TB	
cases	were	diagnosed	accurately	with	the	Xpert	test.		The	MDR-TB	rate	was	5.8%.		The	index	
test	was	therefore	more	sensitive	and	lead	to	faster	access	to	test	results	than	the	gold	
standard.	
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Tables	
Table	1.	Clinical	and	radiological	red	flags	on	which	the	suspected	diagnosis	of	TB	was	
made.	
Clinical	Red	Flags	 Radiological	Red	Flags	
• History	of	chronic	pain	for	more	than	3	months	
• Constitutional	symptoms:	low	grade	fever,	night	sweats,	loss	of	appetite,	weight	loss	
• Chronic	cough	
• Elevated	ESR	
• History	of	Tuberculosis	contact	
• Gibbus	
• Neurological	deficit	
• Positive	Mantoux	test	
• Immune	compromise/HIV	
• Loss	of	anterior	vertebral	height	
• Paravertebral	shadow	on	XRs	
• Shadow	of	a	psoas	abscess	
• Adjacent	Vertebral	endplate	changes	with	preserved	disc	height	
• Changes	on	Chest	X-Ray	suspicious	of	TB	
• Paravertebral	abscess	on	MRI			
	
Table	2.	Baseline	characteristics	of	the	patient	cohort.	
	 Overall	 Definite	TB	 Probable	TB	 Not	TB		 P	value	
N	 69	 36	 8	 26	 0.28	
HIV		+	 22	(31.9%)	 13	(36.1%)	 4	(50.0%)	 5	(20.0%)	 0.28	
Sex	(male)	 31	(44.9%)	 14	(38.9%)	 6	(75.0%)	 11	(44.0%)	 0.18	
Age	-Median	(IQR)	 40	(27	-	60)	 31	(27	-	46)	 37.5	(23	-	57.5%)	 51	(40	-	63)	 0.06	
Xpert		+	 44/69	(63.8%)	 35/36	(97.2%)	 8/8	(100.0%)	 1/25	(4.0%)	 	
 
Table	3.	Per	sample	accuracy	of	Xpert	MTB/RIF	for	detecting	TB.		PPV:	positive	predictive	
value.		NPV:	negative	predictive	value.	
Reference	Standard	 All	(N)	 Sensitivity	%	(N)	 Specificity	%	(N)	 PPV	%	(N)	 NPV	%	(N)	
TB	Culture	or	histology	
positive	
71	 95.6%	(44/46)	 96.2%	(25/26)	 97.7%(44/45)	 92.6%	(25/27)	
TB	Culture	positive	
only	
71	 92.6%	(25/27)	 79.5%	(35/44)	 73.5%	(25/34)	 94.6%	(35/37)	
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Chapter	4	
Diagnostic	accuracy	of	Xpert	MTB/RIF	in	HIV	positive	and	HIV	negative	patients	with	
musculoskeletal	tuberculosis		
This	has	been	submitted	to	the	Bone	&	Joint	Journal	(BJJ),	formerly	known	as	The	Journal	of	
Bone	&	Joint	Surgery	(British	Volume),	published	by	The	British	Editorial	Society	of	Bone	&	
Joint	Surgery.			
M	Held1,	M	Laubscher1,	L	Workman2,	HJ	Zar2,	R	Dunn1	
Affiliation:	
	
1Orthopaedic	Research	Unit,	Department	of	Orthopaedic	Surgery,	Groote	Schuur	Hospital	
University	of	Cape	Town	
Address:	H49	Old	Main	Building,	Groote	Schuur	Hospital,	Observatory	7925,	South	Africa	
	
2Department	of	Pediatrics	and	Child	Health,	Red	Cross	War	Memorial	Children’s	Hospital		
University	of	Cape	Town	and	MRC	Unit	on	Child	&	Adolescent	Health,	University	of	Cape	
Town,	South	Africa		
Address:		Klipfontein	Road,	Rondebosch	7700,	South	Africa	
	
	
	
	
Keywords	
Tuberculosis,	Xpert,	accuracy,	osteoarticular,	musculoskeletal,	bone	and	joint,	extraspinal,	
spine,	Pott’s	disease,	tissue	biopsy	
	
	 36	
Abstract	
	
Aim	
We	aimed	to	investigate	the	diagnostic	accuracy	of	Xpert	MTB/RIF	(Xpert)	in	musculoskeletal	
TB	of	HIV	positive	and	negative	patients.		
Methods	
A	prospective	study	of	patients	older	than	13	years	of	age	with	suspected	TB	of	bone	and	
joints,	who	presented	to	a	large	tertiary	care	hospital	in	South	Africa	was	undertaken	from	
June	2013	to	March	2015.	The	diagnostic	accuracy	of	Xpert	was	compared	to	culture	or	
histopathology	as	the	gold	standard.		
Results	
206	biopsies	of	201	patients	(23%	HIV	positive)	were	evaluated.	The	sensitivity	and	
specificity	of	Xpert	was	92.3%	and	99.1%	respectively.	Xpert	detected	8	cases	more	than	
culture	(p	=	0.069)	and	positive	results	were	available	17	days	earlier	(<0.001).	Xpert	
detected	all	four	multidrug	resistant	TB	(MDR-TB)	cases	and	an	additional	two	rifampicin	
resistant	cases	in	culture	negative	samples.	The	sensitivity	of	Xpert	in	HIV	positive	patients	
was	96.9%	(31/32)	versus	89.6%	(43/48)	in	HIV	negative	patients	(p=0.225).		
Conclusion	
Xpert	is	an	accurate	test	for	the	diagnosis	of	musculoskeletal	TB	in	HIV	positive	and	HIV	
negative	patients.	A	positive	Xpert	result	should	be	regarded	as	microbiologic	confirmation	
of	osteoarticular	TB.	
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Introduction	
Musculoskeletal	TB	occurred	in	approximately	3%	of	the	estimated	8.6	million	people	who	
developed	tuberculosis	(TB)	in	2012.2	Amongst	these,	spinal	TB	is	the	most	common	
orthopaedic	manifestation,	and	may	lead	to	neurological	deficits	in	23-76%	of	cases.	21	
Timely	and	accurate	diagnosis	of	musculoskeletal	TB	with	initiation	of	appropriate	therapy	is	
crucial	to	prevent	such	associated	morbidity.	
In	a	recent	meta-analysis,	Xpert®	MTB/RIF	(Cepheid,	Sunnyvale,	CA)	was	reported	to	have	a	
sensitivity	of	90%	for	M	tuberculosis	and	of	94%	for	rifampicin	resistance	in	pulmonary	TB	in	
adults.56	 In	a	 second	meta-analysis	of	 the	accuracy	of	Xpert	on	 tissue	 samples	 (other	 than	
lymph	 nodes)	 using	 culture	 as	 a	 reference	 standard39	 the	 reported	 pooled	 sensitivity	was	
81.2%	(95%	CI,	67.7	–	89.0%)	and	specificity	was	98.1%	(95%	CI,	87.0	–	99.8%).	However,	there	
are	no	large	published	studies	on	the	accuracy	of	Xpert	for	musculoskeletal	disease	in	either	
HIV-infected	 or	 uninfected	 adults.	 	 Non-automated	 nucleic	 acid	 amplification	 assays	 have	
reported	sensitivities	of	61%	-	83%	for	musculoskeletal	TB.37,	68-71	A	 few	small	 studies	have	
investigated	Xpert	for	musculoskeletal	disease	including	a	small	pilot	study	we	undertook,19	a	
case	report72	and	a	study	of	29	spinal	tissue	samples.65	In	this	study	the	reference	standard	
was	based	on	clinical	and	radiological	findings.	Xpert	had	a	sensitivity	of	72%	in	HIV	negative	
and	82%	in	HIV	positive	patients.	However,	Xpert	was	not	done	onsite	and	results	were	only	
available	at	approximately	six	days,	compared	to	27	days	for	culture.	
This	study	aimed	to	assess	the	accuracy	of	Xpert,	for	musculoskeletal	TB	in	HIV	infected	and	
uninfected	adults.	We	also	compared	the	time	to	availability	of	results	for	Xpert	to	that	of	
culture	and	differences	in	accuracy	in	spinal	and	extra-spinal	samples.			
	
Methods	
A	prospective	study	of	consecutive	patients	older	then	13	years	of	age	with	clinico-
radiological	features	of	musculoskeletal	TB	was	done.		All	patients	underwent	a	
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musculoskeletal	tissue	biopsy	for	suspected	TB	from	June	2013	to	March	2015	as	part	of	the	
routine	clinical	workup.	Included	were	patients	who	presented	to	our	institution,	a	large	a	
tertiary	care	hospital	in	South	Africa,	with	symptoms	suspicious	of	TB	and	the	fact	that	the	
patients	had	received	the	Xpert	assay.	Excluded	were	samples	in	which	Xpert	or	TB	cultures	
were	faulty,	insufficient	or	contaminated.			
Clinical	features	and	red	flags	for	suspected	TB	were	defined	as	the	presence	of	
constitutional	symptoms,	chronic	cough,	elevated	ESR,	history	of	TB	contact,	spinal	gibbus,	
neurological	deficit	in	suspected	spinal	TB,	history	of	pain	for	more	than	3	months,	and	
immune	compromise	or	HIV.		Radiological	features	for	suspected	TB	were	loss	of	anterior	
vertebral	height,	paravertebral	shadow	on	radiographs,	shadow	of	a	psoas	abscess,	adjacent	
vertebral	endplate	changes	with	preserved	disc	height,	changes	on	chest	radiographs	
suspicious	of	TB	and	paravertebral	abscess	formation	on	MRI.	Biopsies	were	performed	by	a	
specialized	orthopaedic	service	at	our	hospital.		
Musculoskeletal	tissue	samples	were	collected	surgically	in	an	operating	room	under	sterile	
conditions	from	radiographically	predetermined	areas	of	disease.	Tissue	samples	were	taken	
from	synovium	in	articular	biopsies	and	bone	in	extra-articular	biopsies.		Spinal	tissue	
biopsies	were	performed	by	a	subspecialist	surgical	spinal	team.	Extraspinal	lesions	were	
biopsied	by	a	specialised	orthopaedic	team.		Extraspinal	biopsies	were	done	by	open	
approach	and	dissection	to	the	area	of	suspected	disease.	Indications	for	open	spinal	
biopsies	included	instability,	deterioration	of	neurology,	a	large	abscess	or	airway	
compromise.	
Specimens	were	submitted	in	sterile	saline	in	duplicate	to	the	microbiology	laboratory	to	be	
processed	simultaneously.	The	first	specimen	was	processed	for	Xpert®	MTB/RIF	(Xpert)	
testing	(Cepheid,	Sunnyvale,	CA).	Xpert	SR	lysis	buffer	was	added	in	a	1:3	ratio	and	the	
specimen	was	vortexed	initially	and	again	after	ten	minutes.	Two	millilitres	of	the	mixture	
were	processed	automatically	and	the	result	was	read	after	approximately	90	minutes.	A	
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trained	laboratory	technician	blinded	to	the	results	of	the	reference	test	performed	Xpert	
testing.	
The	reference	standard	was	liquid	culture	or	histology.		Culture	was	done	on	the	second	
specimen	using	the	automated	liquid	culture	BACTEC	MGIT	system	(960	by	Diagnostic	
Systems,	Sparts	MD	(Franklin,	Lakes,	NJ,	USA).	A	Ziehl-Nielson	(ZN)	stain	and	a	haematoxylin	
and	eosin	(HE)	stain	were	done	in	the	microbiology	and	histopathology	laboratory	
respectively.		
Quantification	of	acid-fast	bacilli	(AFB)	was	according	to	the	specifications	from	the	Centres	
for	Disease	Control	and	Prevention.	“MDR-TB”	was	defined	as	resistance	to	isoniazid	and	
rifampicin.	The	isolate	was	assessed	for	multidrug	resistant	TB	(MDR-TB)	using	the	
GenoType®	MTBDRplus	or	GenoType®	Mycobacterium	CM	lineprobe	assays	(Hain	
Lifescience,	Nehren,	Germany).	Lineprobe	assays	are	PCR	tests,	which	can	detect	TB	and	
identify	rifampicin	resistant	strains	by	detecting	mutations	of	the	rpoB	gene.	Mutations	in	
the	the	katG	gene	or	inhA	gene	can	be	detected	and	are	used	for	testing	isoniazid	
resistance.	Lineprobe	assays	need	at	least	regional	level	laboratories	due	to	their	complexity	
and	bio	safety	requirements.	
A	trained	pathologist	experienced	in	diagnosing	TB	reviewed	the	histopathology	slides.	
Clinical	data,	imaging,	as	well	as	the	Xpert	test	results	were	available	to	the	pathologist.	
Histological	criteria	for	TB	were	caseous	necrosis,	epitheloid	cell	granulomas	or	Langerhans	
giant	cells.			
“Confirmed	TB”	was	defined	as	a	positive	M	tuberculosis	culture	or	positive	histology.		A	
case	was	considered	to	be	“NOT	TB”	if	culture	and	histology	were	negative	and	where	there	
was	improvement	on	follow-up	without	TB	treatment.	The	diagnostic	accuracy	of	Xpert	
(Cepheid,	Sunnyvale,	CA,	USA)	was	compared	to	liquid	culture	or	histology.	
The	study	was	approved	by	the	human	research	ethics	committee	of	the	Faculty	of	Health	
Sciences,	University	of	Cape	Town	and	was	performed	in	accordance	with	the	Helsinki	
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Declaration	(1964,	amended	in	2008)	of	the	World	Medical	Association	(See	Appendix).	
Written	consent	was	obtained	in	all	patients.			
	
Statistical	Analysis	
The	sensitivity,	specificity	and	predictive	values	of	Xpert	with	95%	confidence	intervals	(95%	
CI)	were	calculated	using	TB	culture	or	histology	as	the	reference	standard.	Data	were	
analysed	as	per	sample	using	STATA	13	statistical	software	(STATA	Corporation,	College	
Station,	TX	USA).	Descriptive	statistics	were	used	to	characterise	the	study	population,	
normally	distributed	continuous	data	were	summarized	by	mean	and	95%	confidence	
intervals	and	non-normally	distributed	continuous	data	by	median	and	interquartile	range.	
Categorical	data	were	summarized	as	proportions	with	95%	confidence	intervals.	Statistical	
tests	included	two-sample	test	of	proportions,	chi	squared	test,	Kruskal	Wallis	test	and	
Wilcoxon	rank-sum	test.	All	statistical	tests	were	two-sided	at	α	=	0.05.	
	
Results	
207	samples	were	collected	from	202	patients	with	suspected	musculoskeletal	TB;	5	patients	
had	repeat	biopsies.		One	sample	was	excluded	as	the	culture	sample	was	sent	in	formalin	
and	had	to	be	discarded,	206	samples	met	the	inclusion	criteria.	The	biopsy	sites	are	shown	
in	Table	1;	122	of	206	biopsies	(59.2%)	were	done	for	spinal	TB.	The	remaining	biopsies	were	
for	suspected	extra-spinal	TB	of	joint	or	bone.	196	(95.1%)	were	tissue	samples	and	ten	
(4.8%)	were	pus	samples.	The	median	age	of	the	patients	was	40	years	(IQR	27-54),	97	were	
male	(48.3%).	In	the	per	sample	analysis	76	(38.5%)	were	culture	positive	(definite	TB)	of	
which	Xpert	was	positive	in	85	samples	(41.3%)	(Table	2).			
The	sensitivity	for	Xpert	in	musculoskeletal	samples	was	92.3%	(95%	CI	84.8	–	96.9)	with	
specificity	of	99.1%	(95%	CI	95.2	–	99.8)	(Table	2).		
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For	culture	confirmed	TB	only,	the	sensitivity	of	Xpert	was	90.8%	(95%	CI	81.9	–	96.2,	
P=0.724)	with	specificity	of	87.7%	(95%	CI	80.8	–	92.8,	P<0·001).		All	except	one	of	the	
culture	negative	but	Xpert	positive	samples	showed	features	of	TB	on	histology.			
In	203	of	206	samples	(98.5%)	a	Ziehl-Nielson	Stain	was	available	for	quantification	of	Acid	
Fast	Bacilli	(AFB),	32	(15.8%)	were	positive,	and	171	(84.2%)	were	negative.		The	sensitivity	
when	compared	to	our	gold	standard	was	33.7%	(95%	CI	24.2%	-	44.3%)	with	a	specificity	of	
99.1%	(95%	CI	95.1%	-	99.9%)	(Table	2).	
Xpert	was	positive	at	a	median	(IQR)	of	1	day	(1	–	1)	compared	to	18	days	(12	–	26)	for	
culture,	p	<0.001.	Xpert	detected	more	cases	than	culture	(84/91;	92.3%	compared	to	
76/91;	83.5%	on	culture	p	=	0.069).			
Drug	resistant	TB:	All	four	MDR-TB	cases	detected	with	the	lineprobe	assay	were	also	
correctly	identified	with	Xpert.	Xpert	detected	an	additional	two	patients	with	rifampicin	
resistance,	in	which	culture	was	negative	(Table	3).	Therefore	6	of	90	patients	(6.7%)	with	TB	
disease	had	rifampicin	resistance.		In	one	case	isoniazid	(INH)	mono-resistance	was	found	on	
line	probe	assay.			
Accuracy	in	samples	of	HIV	infected	and	uninfected	patients:	Forty-six	patients	were	HIV	
infected	(22.9%),	102	patients	were	HIV	uninfected	(50.7%)	and	53	(26.4%)	were	of	
unknown	HIV	status.	Amongst	HIV	infected	patients,	32	of	46	(69.5%)	had	TB	compared	to	
47	of	102	HIV	negative	patients	(46.1%)	and	11	of	the	55	patients	with	unknown	HIV	status	
(20.7%);	p	<0.001	(Table	1).	The	sensitivity	of	Xpert	was	96.9%	(95%	CI	83.8-99.9)	in	HIV	
positive	compared	to	89.6%	(95%	CI	77.3-96.5,	p=0.225)	HIV	negative	patients.	The	
specificity	was	100%	(95%	CI	78.5-100.0)	for	HIV	positive	compared	to	98.3%	(95%	CI	90.8-
99.9,	p=0.621)	in	HIV	negative	individuals.	(Table		4).	
Accuracy	in	spinal	and	extra-spinal	samples:	The	sensitivity	of	Xpert	for	spinal	biopsies	was	
93.8%	(95%	CI	86.0-97.9)	with	specificity	of	97.6%	(95%	CI	87.4	–	99.9),	compared	to	extra-
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spinal	biopsies	with	a	sensitivity	of	81.8%	(95%	CI	48.2	–	99.7,	p=0.164)	and	specificity	of	
100%	(95%	CI	95.1-100%,	p=0.186)(Table	4).	
	
Discussion	
This	is	the	first	large	study	to	investigate	the	accuracy	of	Xpert	for	the	diagnosis	of	
musculoskeletal	TB	in	both	HIV	positive	and	negative	patients.	We	found	that	Xpert	had	high	
sensitivity	and	specificity	for	spinal	and	extra-spinal	disease	and	provided	additional	
diagnostic	yield	over	culture.	We	noted	a	higher	accuracy	than	reported	in	a	meta-analysis	
evaluating	Xpert	in	extrapulmonary	TB.39	In	addition,	Xpert	was	more	sensitive	than	non-
automated	nucleic	acid	amplification	assays	in	musculoskeletal	TB	reported	in	other	studies	
with	sensitivities	of	61%	-	83%.37,	68-71	Reliance	on	culture	may	lead	to	delay	in	diagnosis	and	
treatment,	with	resultant	serious	morbidity	such	as	joint	destruction	or	paralysis	in	spinal	
TB.21	The	results	for	Xpert,	including	drug	resistance,	were	available	much	faster	than	liquid	
culture	enabling	timely	diagnosis	and	initiation	of	therapy.		
A	further	advantage	of	Xpert	is	the	ability	to	rapidly	detect	resistant	cases,	which	is	
especially	important	in	our	setting	with	one	of	the	highest	prevalence	rates	of	drug	resistant	
disease	worldwide.	2	A	meta-analysis	of	Xpert	for	resistance	testing	in	tissue	of	566	samples	
from	13	studies,	reported	the	prevalence	of	Rifampicin	resistance	to	be	5.4%.	Xpert	missed	2	
of	41	rifampicin	resistant	samples.39	We	found	4	(4.4%)	patients	with	MDR-TB	and	Xpert	
detected	an	additional	2	cases	of	rifampicin	resistant	TB	who	were	culture	negative.	
Therefore	6	patients	(6.7%)	had	rifampicin	resistant	TB	and	Xpert	detected	all	correctly.		The	
use	of	Xpert	in	these	cases	enabled	rapid	initiation	of	appropriate	therapy	and	detected	
another	2	cases,	which	would	have	been	missed	otherwise.	A	limitation	of	Xpert	is	its	
inability	to	detect	INH	mono-resistance,	which	was	the	case	in	one	sample,	yet	the	
treatment	is	identical	to	that	for	drug-sensitive	TB	in	South	Africa.	73	
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Xpert	had	a	similar	sensitivity	in	samples	from	HIV	positive	compared	to	HIV	negative	patients.	
This	trend	has	also	been	reported	in	another	small	study.65	HIV	positive	patients	may	be	at	
particular	risk	for	rapid	progression	of	disease	and	morbidity,1	therefore	use	of	Xpert	may	be	
especially	useful	in	such	populations.		
A	limitation	of	the	study	is	that	it	was	conducted	amongst	adult	patients	with	advanced	
disease	requiring	surgery	at	a	referral	hospital.	The	generalizability	of	these	results	to	
patients	with	less	severe	disease	is	therefore	unclear;	further	studies	of	patients	with	milder	
forms	of	musculoskeletal	disease	and	in	peripheral	hospitals	should	be	done.	A	further	
limitation	is	that	the	histological	diagnosis	was	made	by	a	single	pathologist.	However,	clear	
criteria	for	histopathological	diagnosis	were	used,	and	the	biopsies	were	consistently	
reviewed	in	a	standardized	way	by	an	experienced	pathologist.	We	also	did	not	blind	the	
pathologist	to	the	Xpert	results,	which	might	have	introduced	bias.	Though	test	results	are	
usually	not	part	of	the	information	given	or	retrieved	by	the	pathologists	at	the	time	of	the	
analysis	of	the	specimen.	Different	methods	of	sample	collections	were	used,	guided	by	the	
anatomic	area	as	well	as	severity	of	the	disease,	which	could	have	potentially	resulted	in	
suboptimal	sample	collection.	More	aggressive	(open)	approaches	might	have	resulted	in	a	
standardized	way	of	surgical	sample	collection	but	may	have	resulted	in	unacceptable	
morbidity.	A	further	limitation	was	that	in	several	patients	the	HIV	status	was	unknown,	thus	
reducing	the	sample	size	for	comparison	of	HIV	positive	and	negative	adult	patients.				
Conclusions	
Xpert	is	an	accurate,	rapid	and	effective	test	for	the	diagnosis	of	musculoskeletal	TB	in	HIV	
positive	and	HIV	negative	individuals.	It	should	be	recommended	as	a	first	line	investigation	
for	musculoskeletal	TB	and	a	positive	result	should	be	regarded	as	microbiologic	
confirmation	of	musculoskeletal	TB.	
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Tables	
Table	1.		Characteristics	of	patient	cohort	and	biopsy	sites.			
  
Overall 
TB Culture 
positive only  
TB Culture negative 
but histology positive  
Not TB  P value 
N (%) of patients 201 75 (37.3) 15 (7.5) 111 (55.2)  
HIV infected 
HIV uninfected 
HIV status unknown 
46 (22.9) 
102 (50.7) 
53 (26.4) 
24 (32.0) 
41 (54.7) 
10 (13.3) 
8 (53.3) 
6 (40.0) 
1 (6.7) 
14 (12.6) 
55 (49.6) 
42 (37.8) 
 
<0.001 
Sex (male) 97 (48.3) 33 (44.0) 9 (60.0) 55 (49.6) 0.485 
Age -Median (IQR) 40 (27 – 54) 35 (25 – 51) 35 (24 – 52) 47 (28 – 57) 0.099 
 
Biopsy Sites 
 
N  
 
% 
Spine 122 59.2 
Hip 10 4.8 
Knee 30 14.6 
Ankle and foot 9 4.4 
Shoulder 6 2.9 
Elbow 5 2.4 
Wrist/Hand 3 1.5 
Bone 20 9.7 
Sacroiliac joint 1 0.5 
Total 206 100 
N=Number, IQR=Inter Quartile Range. 
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Table	2.	Per-sample	comparison	of	the	accuracy	of	TB	culture	to	Xpert	with	the	reference	standard	set	as	TB	
culture	or	histology	positive.		
Reference Standard 
TB culture or histology 
positive (N = 84) 
All (N) 
samples 
Sensitivity % (N) 
CI 95% 
Specificity % (N) 
CI 95% 
PPV % (N) 
CI 95% 
NPV % (N) 
CI 95% 
TB Culture  76/206 
(36.9%) 
76/91 
83.5 (74.3 – 90.5) 
115/115 
100 (96.8 – 100) 
76/76 
100.0 (95.2 – 100) 
115/130 
88.5 (81.7 – 93.4) 
Xpert 85/206 
(41.3%) 
84/91 
92.3 (84.8 – 96.9) 
114/115 
99.1 (95.2 – 99.8) 
84/85 
98.8 (93.6 – 99.8) 
114/121 
94.2 (88.4 – 97.6) 
P-Value  0.069 0.316 0.343 0.107 
AFB 203/206 
(98.5%) 
31/92 
33.7 (24.2 – 44.3) 
110/112 
99.1 (95.8 – 99.9) 
31/32 
96.9 (83.8 – 99.9) 
110/171 
64.3 (56.7 – 71.5) 
N = number of patients. PPV = positive predictive value. NPV = Negative predictive value. AFB = evidence of acid fast bacilli 
on Ziehl-Nielson stain. 
 
Table	3.	Concordance	between	Xpert	and	culture	drug	susceptibility	testing	for	rifampicin	
resistance.	
 Culture 
resistant 
Culture 
sensitive  
Culture 
inconclusive  
Culture 
negative 
Total 
Xpert resistant  4 0 0 2 6 
Xpert sensitive  0 64 1 13 78 
Xpert Inconclusive 0 1 0 0 1 
Xpert negative 0 7 0 114 121 
 4 72 1 129 206 
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N = number of patients. PPV = positive predictive value. NPV = Negative predictive value. 
 
	
	
 
4.		Accuracy	of	Xpert	in	samples	comparing	HIV	positive	to	HIV	negative	patients	as	well	as	spinal	
to	extra	spinal	samples.		
Reference Standard 
TB Culture or 
histology positive 
All N 
(%) 
TP FP FN TN Sensitivity N% 
CI 95% 
Specificity N% 
CI 95% 
PPV N% 
CI 95% 
NPV N% 
CI 95% 
Over all (samples) 206 84 1 7 114 
84/91 
92.3  
(84.8–96.9) 
114/115 
99.1  
(95.3–100) 
84/85 
98.8  
(93.6 –100) 
114/121 
94.2  
(88.4–97.6) 
SPINAL VERSUS EXTRASPINAL SAMPLES 
Spinal biopsies 
122 
(59.2) 
75 1 5 41 
75/80 
93.8  
(86.0 – 97.9) 
41/42 
97.6  
(87.4 – 99.9) 
75/76 
98.7  
(92.9–99.9) 
41/46 
89.1  
(76.4–96.4) 
Extraspinal biopsies 
84 
(40.8) 
9 0 2 73 
9/11 
81.8  
(48.2 – 97.7) 
73/73 
100  
(95.1 – 100) 
9/9 
100  
(70.1–100) 
73/75 
97.3  
(90.7–99.7) 
P-value      0.164 0.186 0.729 0.061 
HIV NEGATIVE VERSUS HIV POSITIVE SAMPLES 
HIV negative 
106 
(51.5) 
43 1 5 57 
 
43/48 
89.6  
(77.3 – 96.5) 
 
57/58 
98.3  
(90.8 – 99.9) 
43/44 
97.7  
(88.0–99.9) 
57/62 
91.9 
(82.2–97.3) 
HIV positive 
46 
(22.3) 
31 0 1 14 
31/32 
96.9  
(83.8 – 99.9) 
14/14 
100  
(78.5 – 100) 
31/31  
100 
(90.0–100) 
14/15  
93.3 
(68.1–99.8) 
P-Value      0.225 0.621 0.398 0.856 
HIV unknown 
54 
(26.2) 
10 0 1 43 
10/11 
90.9  
(58.7 – 99.8) 
43/43 
100  
(91.8 – 100) 
10/10 
100  
(72.2 –100) 
43/44 
97.7  
(88.0–99.9) 
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Chapter	5	
Diagnostic	accuracy	of	Xpert	MTB/RIF	in	tissue	samples	of	children	with	suspected	
musculoskeletal	TB	
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Abstract	
Aim	
Xpert	MTB/RIF	(Xpert)	is	useful	for	the	diagnosis	of	extrapulmonary	TB	in	adults,	but	there	is	
limited	evidence	on	its	usefulness	in	children.	This	study	investigated	the	accuracy	of	Xpert	
for	the	diagnosis	of	childhood	musculoskeletal	TB.	
	
Methods	
The	diagnostic	accuracy	of	Xpert	was	compared	to	a	reference	standard	of	culture	or	
histopathology	in	children	hospitalized	with	suspected	osteoarticular	TB	in	Cape	Town,	
South	Africa	from	June	2013	to	May	2015.		
	
Results	
109	samples	of	102	patients	(60	male;	58.8%)	with	a	median	age	of	5.6	years	(IQR	2.2	–	8.7)	
were	included.	There	were	23	samples	with	confirmed	TB	by	culture	or	histology	(21.1%);	
histology	was	positive	in	all	of	these,	while	culture	was	positive	in	14	samples	(12.8%).	Xpert	
was	positive	in	17	samples	(15.6%),	providing	a	sensitivity	of	73.9%	(95%	CI	51.6-89.8)	and	
specificity	of	100%	(95%	CI	95.7	-	100).		Xpert	was	positive	at	a	mean	of	0.8	days	(0.46-1.4)	
compared	to	21	days	(19	–	30)	for	culture,	p	<0.001.		Multidrug	resistant	TB	was	detected	on	
culture	in	a	single	sample	that	was	negative	on	Xpert	testing.	
	
Conclusion	
Xpert	confirmed	bone	and	joint	TB	in	children	more	accurately	and	faster	than	culture	and	
should	be	used	as	a	first	line	test.		The	sensitivity	of	Xpert	is	relatively	low	when	compared	
to	histology	which	is	a	useful	test	for	musculoskeletal	TB	in	children.	
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Introduction	
The	World	Health	Organization	(WHO)	estimates	9	million	newly	diagnosed	tuberculosis	
cases	in	2013,	25%	in	Africa	and	more	than	500	cases	per	100.000	inhabitants	in	South	
Africa;	childhood	TB	is	estimated	to	account	for	15-20%	of	the	total	caseload	in	African	
countries.2	Extrapulmonary	disease	accounts	for	10%	to	42%	of	TB	cases,	of	which	around	
10-25%	have	musculoskeletal	TB.	2,1	,3			
At	Red	Cross	Children’s	Hospital	in	Cape	Town,	the	largest	children’s	hospital	in	sub-Saharan	
Africa,	approximately	20	children	under	the	age	of	12	years	are	treated	for	musculoskeletal	
TB	each	year	(60%	spinal	TB,	20%	in	knee,	16%	in	hip	and	less	then	5%	TB	of	the	ankle	or	
upper	limb).18	
The	sensitivity	of	TB	culture	compared	to	a	composite	reference	standard	for	childhood	
musculoskeletal	TB	is	approximately	73%	(70%	in	hips,	71%	in	knees,	70%	in	ankles,	75%	in	
feet	and	ankles).18,	24,	29,	30	Non-automated	nucleic	acid	amplification	tests	in	synovial	joint	
biopsies	of	children	have	a	sensitivity	of	only	40%	when	compared	to	culture	or	histology,23	
highlighting	the	need	for	a	more	accurate	test	for	musculoskeletal	TB.		Accurate	and	timely	
diagnosis	of	musculoskeletal	TB	is	essential	to	prevent	joint	destruction,	growth	arrest,	and	
contractures	in	large	joints	as	well	as	deformity	with	neurological	compromise	in	spinal	
disease,	which	may	lead	to	lifelong	morbidity	and	disability.21-25	Additionally,	MDR	TB	has	a	
prevalence	of	5%	in	musculoskeletal	TB	in	our	population19	making	a	correct	diagnosis	on	
tissue	biopsy	imperative	to	identify	resistance	and	initiate	optimal	treatment.			
The	Xpert®	MTB/RIF	(Xpert)	assay	(Cepheid,	Sunnyvale,	CA)	is	an	automated	nucleic	acid	
amplification	test,	which	has	been	validated	for	pulmonary	TB	in	children	but	not	for	
musculoskeletal	TB.		At	Red	Cross	Hospital,	the	sensitivity	of	Xpert	compared	to	liquid	
culture,	on	repeated	induced	sputum	specimens	for	PTB	is	approximately	70%58	and	in	a	
recent	meta-analysis59	the	pooled	sensitivity	of	a	single	Xpert	was	62%.			
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Data	on	Xpert	of	bone	and	joint	tissue	samples	are	very	limited.	One	study	on	29	adults	with	
spinal	disease	reported	a	sensitivity	of	72%	in	HIV	negative	and	82%	in	HIV	positive	patients,	
but	this	was	compared	to	a	clinical	reference	standard.65	Another	study	66	compared	Xpert	in	
60	adult	orthopaedic	fluid	samples	with	a	composite	reference	standard	and	found	a	
sensitivity	of	82%	(41/50)	versus	culture	with	a	sensitivity	of	48%	(24/50).	Currently	no	large	
studies	have	assessed	the	accuracy	of	Xpert	in	childhood	osteoarticular	TB.		We	therefore	
aimed	to	assess	the	diagnostic	accuracy	of	Xpert	in	bone	and	joint	samples	of	children	with	
suspected	musculoskeletal	TB.		
	
Methods	
A	prospective	study	of	Xpert	for	diagnosis	of	musculoskeletal	TB	was	done	in	children	
admitted	to	Red	Cross	Children’s	Hospital	in	Cape	Town,	South	Africa,	from	June	2013	to	
May	2015.	Children	under	13	years	of	age	who	presented	with	suspected	musculoskeletal	TB	
were	enrolled.		Symptoms	or	signs	suspicious	of	musculoskeletal	TB	included	joint	or	back	
pain	with	insidious	onset,	associated	with	elevated	inflammatory	markers,	TB	contact,	
constitutional	symptoms,	chronic	cough,	or	HIV.	Suspicious	radiological	signs	were	
osteopenia	and	erosions	involving	both	sides	of	the	affected	joint.		In	spinal	imaging,	
anterior	vertebral	height	loss,	paravertebral	or	psoas	shadow	suggesting	abscess	formation,	
adjacent	endplate	changes	with	preserved	disc	height	as	well	as	local	kyphosis	were	
suggestive	of	TB.		Children	were	excluded	if	samples	were	inadequate	or	incorrectly	
processed	or	tested.		Informed	consent	was	taken	from	a	parent	or	legal	guardian.	
After	informed	consent	was	taken	from	a	parent	or	legal	guardian,	radiologically	
predetermined	areas	of	disease	were	biopsied	surgically	as	part	of	the	routine	clinical	
workup.		This	was	done	through	an	open	approach,	under	sterile	conditions	and	general	
anaesthesia.	Spinal	biopsies	were	performed	by	a	subspecialist	spinal	unit.		A	subspecialist	
paediatric	orthopaedic	unit	performed	all	extraspinal	biopsies.	
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“Confirmed	TB”	was	defined	as	a	positive	M	tuberculosis	culture	or	positive	histology.		A	
negative	culture	and	histology	with	improvement	of	symptoms	without	TB	treatment	after	
at	least	a	month	of	follow	up	was	considered	‘NOT	TB’.	Improvement	was	assessed	by	
means	of	a	decrease	in	ESR	readings,	signs	of	sclerosis	on	XR,	as	well	as	clinical	improvement	
such	as	weight	gain	and	diminished	pain.	
The	accuracy	of	Xpert	was	compared	to	culture	or	to	histology	as	a	reference	standard.		
Tests:	Specimens	were	collected	in	duplicate	and	sterile	saline	was	added.		One	specimen	
was	used	for	Xpert®	MTB/RIF	testing	(Cepheid,	Sunnyvale,	CA).	The	specimen	was	mixed	
with	Xpert	SR	lysis	buffer	at	a	ratio	of	1:3.	Two	millilitres	of	this	fluid	were	automatically	
processed	adhering	to	Xpert	protocols.	The	laboratory	technician	processing	the	Xpert	test	
was	blinded	to	the	culture	or	histology	results.	
The	primary	reference	standard	was	TB	culture	on	BACTEC	MGIT	960	[Diagnostic	Systems,	
Sparts	MD,Franklin,	Lakes,	NJ,	USA)	or	histology.		The	microbiology	and	histopathology	
laboratories	performed	Ziehl-Nielson	(ZN)	stains	and	haematoxylin	and	eosin	(HE)	stains	
respectively.		Specifications	from	the	Centres	for	Disease	Control	and	Prevention	were	used	
for	quantification	of	acid-fast	bacilli	(AFB).	The	pathologist	was	blinded	to	the	Xpert	and	
culture	results	but	not	to	the	clinical	history.	TB	was	diagnosed	if	histology	showed	
granulomatous	necrosis	with	epitheloid	cells	or	Langhans	giant	cells		
The	culture	isolate	was	tested	for	drug	resistance	using	the	GenoType®	MTBDRplus	or	
GenoType®	Mycobacterium	CM	lineprobe	assay	(Hain	Lifescience,	Nehren,	Germany).	
“MDR-TB”	was	defined	as	resistance	to	isoniazid	and	rifampicin,	with	or	without	resistance	
to	other	first-line	drugs.7		
Statistical	Analysis:	The	accuracy	of	Xpert	(sensitivity,	specificity	and	predictive	values)	with	
95%	confidence	intervals	(95%	CI)	was	calculated	using	positive	TB	culture	or	histology	for	M	
tuberculosis	as	the	reference	standard.		Per	sample	analysis	was	done	using	STATA	13	
statistical	software	(STATA	Corporation,	College	Station,	TX	USA).	The	study	population	was	
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analysed	using	descriptive	statistics,	mean	and	95%	confidence	intervals	were	used	in	
normally	distributed	data,	median	and	interquartile	range	was	used	for	non-normally	
distributed	continuous	data.	Categorical	data	were	reported	as	proportions	with	95%	
confidence	intervals.	Statistical	tests	included	two-sample	test	of	proportions,	chi	squared	
test,	Kruskal	Wallis	test	and	Wilcoxon	rank-sum	test.	All	statistical	tests	were	two-sided	at	α	
=	0.05.	
	
Results	
We	collected	120	samples	from	113	patients;	three	patients	had	repeat	biopsies	and	one	
patient	had	multiple	biopsies	of	different	sites.		Of	120	samples,	11	were	excluded	(7	TB	
cultures	were	contaminated	and	four	samples	were	incorrectly	processed	or	tested).	
Therefore	109	samples	from	102	patients	(60	male;	58.8%)	with	a	median	age	of	5.6	years	
(IQR	2.2	–	8.7)	were	included.		In	30	patients	(29.4%)	the	HIV	status	was	known,	3/30	(10%)	
were	HIV	positive,	27/30	(90%)	were	HIV	negative.		
The	biopsy	sites	are	shown	in	Table	1.	The	main	areas	of	biopsy	were	the	knee	(48	of	109	
biopsies;	44.0%),	hip	(18	biopsies;	16.5%),	spine	(14	biopsies;	12.8%),	and	foot	or	ankle	(11	
biopsies;	10.1%).			One	pus	sample	(0.9%)	and	108	(99.1%)	tissue	samples	were	collected.		In	
23	samples	(21.1%)	of	22	patients	(one	repeat	biopsy)	the	histology	was	positive.		Culture	
was	positive	in	14	samples	(12.8%),	all	of	which	also	had	histology	indicating	TB.		A	total	of	
23	samples	(21.1%)	were	therefore	histology	or	culture	positive	(confirmed	TB).		Xpert	was	
positive	in	17	(15.6%)	samples	and	detected	3	samples	more	when	compared	to	culture	
(Table	2).	Of	the	109	samples,	86	were	TB	negative,	with	41	(37.6%)	pyogenic	joint	
infections,	35	(32.1%)	acute	or	chronic	synovitic	joint	pathology,	five	(4.6%)	tumors,	and	five	
(4.6%)	samples	without	a	specific	diagnosis	or	abnormal	features.		
When	comparing	Xpert	to	a	gold	standard	of	culture	or	histology	positive	for	TB,	the	
sensitivity	was	73.9%	(95%	CI	51.6-89.8)	and	specificity	100%	(95%	CI	95.7	-	100)	(Table	3).	
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The	sensitivity	of	TB	culture	was	60.9%	(14/23;	95%	CI	38.5-80,	P=0.345)	with	a	specificity	of	
100%	(86/86;	95%	CI	95.7-100)	when	compared	to	histology	confirmed	TB.		Of	the	109	
samples,	108	(99.1%)	were	tested	for	Acid	Fast	Bacilli	(AFB),	of	which	15	(13.8%)	were	
positive.		The	sensitivity	and	specificity	of	smear	compared	to	culture	or	histology	was	60.9%	
(95%	CI	38.5	–	80.3%)	and	98.8%	(95%	CI	93.6%	-	99.9%)	respectively	(Table	3).				
Xpert	was	positive	at	a	mean	(range)	of	0.8	days	(0.46-1.4)	compared	to	21	days	(19	–	30)	for	
culture,	p	<0.001	(Table	4).	Two	samples	were	drug	resistant	on	testing	with	a	line	probe	
assay;	the	first	was	MDR	but	Xpert	was	negative,	while	the	2nd	showed	isoniazid	(INH)	mono-
resistance,	which	cannot	be	detected	with	Xpert	(Table	5).	
	
Discussion	
This	is	the	first	large	report	to	show	the	accuracy	of	Xpert	for	the	diagnosis	of	
musculoskeletal	TB	in	children.	Xpert	provided	results	much	earlier	than	culture	and	
detected	more	TB	cases	than	culture.	Although	the	sensitivity	of	Xpert	was	consistent	with	
that	reported	on	respiratory	specimens	in	childhood	pulmonary	TB,74	the	sensitivity	was	
lower	than	that	published	for	musculoskeletal	samples	in	adults.19,65,70		The	lower	sensitivity	
in	children	may	reflect	paucibacillary	disease	or	relatively	early	disease	compared	to	that	in	
adults.		Culture	provided	additional	information	on	drug	resistance	in	two	cases.	Hence,	our	
local	policy	is	to	use	culture	with	Xpert	and	histology	to	test	for	musculoskeletal	TB	in	
children.			
Histology	was	positive	for	all	children	who	were	culture	positive,	while	some	children	were	
culture	negative	but	positive	on	histology.		Lack	of	viability	of	the	organisms	or	technical	
issues	in	the	laboratory	or	during	transport	of	the	specimen	may	explain	culture	negative	
histology	positive	cases.		Although	it	cannot	provide	microbiologic	confirmation	or	
resistance	testing,	which	is	crucial	in	our	patient	population,	histology	is	therefore	still	
important	to	detect	musculoskeletal	TB.	Xpert	detected	more	cases	of	histology	proven	TB	
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than	did	culture	and	results	were	available	much	sooner	than	for	culture,	however,	an	
advantage	of	culture	was	the	ability	to	detect	drug	resistance	beyond	rifampicin	resistance.				
A	limitation	of	our	study	was	that	some	TB	culture	samples	were	contaminated	or	were	not	
processed	adequately.		The	relatively	small	number	of	HIV	positive	children	limited	the	
power	to	investigate	the	impact	of	HIV	on	the	accuracy	of	Xpert	and	further	research	is	
needed.		The	small	number	of	HIV	positive	children	might	reflect	the	success	of	the	mother	
to	child	HIV	prevention	program.	The	accuracy	for	histology	might	also	not	be	generalizable	
to	a	setting	with	low	TB	burden,	as	our	pathologist	was	experienced	in	and	preconditioned	
for	the	histological	diagnosis	of	TB	given	the	high	incidence	of	TB	in	South	Africa.	
Nevertheless,	the	histological	signs	of	TB	are	clearly	delineated	and	should	be	recognizable	
by	any	pathologist.				
In	conclusion,	Xpert	confirmed	musculoskeletal	TB	in	children	more	accurately	and	faster	
than	liquid	culture,	the	current	gold	standard.	It	should	therefore	be	used	as	a	first	line	test.		
Yet,	the	sensitivity	of	Xpert	is	relatively	low	when	compared	to	histology.	Histology	therefore	
remains	a	useful	test	for	diagnosis	of	musculoskeletal	TB	in	children.	
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Tables	
 
Table	1.	Sites	of	biopsies.	
 
Site Number (%) 
Spine 14 (12.8) 
Hip 18 (16.5) 
Knee 48 (44.0) 
Ankle and foot 11 (10.1) 
Shoulder 3 (2.7) 
Elbow 6 (5.5) 
Wrist/Hand 1 (1.0) 
Bone 8 (7.3) 
Sacroiliac joint 0 (0.0) 
Total 109 (100) 
 
Table	2.		Characteristics	of	children	(per-patient).			
 
Definite TB 
22/102 (21.6%) 
Overall TB culture 
positive  
histology positive 
(culture negative) 
Not TB  P value 
N (%) of patients 102 13 (12.8%) 9 (8.8%) 80 (78.4%)  
Sex (male) 60 (58.8%) 7 (53.9%) 3/9 (33.3) 50/80 (62.5) 0.224 
Median age (months) 
IQR  
66.8  
(26.1 – 104.0) 
51.1 
(40.7 – 82.9) 
60.2 
(48.6 – 121.1) 
68.3 
(22.1 – 109.7) 
0.479 
N=Number, IQR=Inter Quartile Range. 
	
	
Table	3.	Per-sample	comparison	of	the	accuracy	of	TB	culture	to	Xpert	with	the	reference	standard	
set	as	TB	culture	positive	or	histology	positive	(23/109	samples).	
 
*one AFB not done N=108 
 N = number of patients, PPV = positive predictive value, NPV = Negative predictive value. AFB = evidence of acid fast bacilli 
on Ziehl-Nielson stain. 
 
	
Table	4.	Time	to	availability	of	results	(in	days)	
 Time to result (CI 95%) Time to positive result (CI 95%) Time to negative result (CI 95%) 
Xpert 0.8 (0.5 – 1.4) 0.8 (0.3 – 1.9) 0.7 (0.5 – 1.4) 
Culture 44 (43 – 45) 21.5 (19 – 30) 44 (43 – 46) 
P-Value <0.001 < 0.001 <0.001 
 
	
	
Table	5.	Concordance	between	Xpert	and	culture	drug	susceptibility	testing	for	rifampicin	
resistance.	
 
 Culture 
resistant 
Culture 
sensitive  
Culture 
inconclusive  
Culture 
negative 
Total 
Xpert resistant  0 0 0 0 0 
Xpert sensitive  0 9 1 7 17 
Xpert inconclusive 0 0 0 0 0 
Xpert negative 1 2 1 88 92 
Total 1 11 2 95 109 
	
	
 
 
All (N) samples Sensitivity % (N) 
CI 95% 
Specificity % (N) 
CI 95% 
PPV % (N) 
CI 95% 
NPV % (N) 
CI 95% 
Xpert 17 (15.6%) 17/23 
73.9 (51.6 – 89.8) 
86/86 
100.0 (95.7 – 100.0) 
17/17 
100.0 (81.6 – 100.0) 
86/92 
93.5 (86.3 – 97.6) 
AFB only* 15 (13.8%) 15/23 
65.2 (42.7 – 83.6) 
85/85 
100.0 (95.4 – 100.0) 
15/15 
100.0 (79.6 – 100.0) 
85/93 
91.4 (83.8 – 96.2) 
Histology 23 (21.9%) 23/23 
100.0 (85.7 – 100.0) 
82/82 
100.0 (95.5 – 100.0) 
23/23 
100.0 (85.7 – 100.0) 
82/82 
100.0 (95.5 – 100.0) 
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Chapter	6	
Discussion	and	Conclusion		
Discussion	
These	are	the	first	large	studies	on	the	accuracy	of	Xpert®	MTB/RIF	(Cepheid,	Sunnyvale,	CA)	
on	musculoskeletal	TB	in	adults	and	children	as	well	as	in	HIV	positive	and	HIV	negative	
patients.	It	underlines	that	Xpert	should	be	recommended	as	the	initial	test	for	suspected	
musculoskeletal	TB	as	it	is	more	sensitive	and	gives	faster	results	than	the	current	gold	
standard	(culture	and	histology).		
Xpert	was	found	to	have	high	sensitivity	in	adults	which	is	higher	than	reported	in	a	meta-
analysis	evaluating	Xpert	in	extrapulmonary	TB.39	We	also	found	that	Xpert	has	a	lower	
sensitivity	in	musculoskeletal	samples	of	children	than	of	adults,	19,65,70		however	detecting	
more	cases	of	TB	than	culture.		The	lower	sensitivity	in	children	may	reflect	paucibacillary	
disease	or	relatively	early	disease	compared	to	adults.	The	sensitivity	of	Xpert	in	childhood	
musculoskeletal	TB	was	also	consistent	with	that	reported	on	respiratory	specimens	in	
childhood	pulmonary	TB,74	for	which	Xpert	is	the	recommended	first	line	test.	A	further	
finding	was	that	histology	remains	a	useful	test	for	the	diagnosis	of	musculoskeletal	TB.	It	
should	be	used	in	addition	to	Xpert	to	compensate	for	its	lower	sensitivity	observed	in	
children.			
Xpert	 is	also	an	accurate	test	to	detect	rifampcin	resistance	as	all	rifampcin	resistant	cases	
were	correctly	diagnosed.	 	This	 is	 in	 line	with	current	evidence	supporting	 the	accuracy	of	
Xpert	to	detect	resistance	to	rifampicin	in	pulmonary	and	extrapulmonary	samples.39		
We	also	noted	a	rate	of	rifampicin	resistance	of	approximately	5%,	which,	due	to	the	size	of	
our	cohort	and	prospective	data	collection,	represents	important	evidence	of	drug	resistant	
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musculoskeletal	TB.	This	number	is	comparable	to	the	rifampicin	resistance	in	
extrapulmonary	TB	reported	by	the	WHO	in	a	large	metaanalysis.39		
	
We	found	no	significant	difference	in	the	subgroup	analysis	of	spinal	compared	to	extraspinal	
TB,	as	well	as	HIV	positive	compared	to	HIV	negative	patients.		There	was	however,	a	trend	to	
higher	sensitivity	in	spinal	tissue	as	well	as	HIV	positive	patients.		HIV	positive	patients	may	
have	a	greater	bacillary	load	and	therefore	be	more	likely	to	be	Xpert	positive,	as	has	been	
reported	in	a	previous	study	and	as	has	been	reported	for	childhood	pulmonary	TB.65,	74	HIV	
positive	patients	may	be	at	particular	 risk	 for	 rapid	progression	of	disease	and	morbidity,1	
therefore	use	of	Xpert	may	be	especially	useful	in	such	populations.		
A	major	benefit	of	Xpert	is	its	rapid	time	for	test	results	to	be	available	including	Rifampicin	
resistance,	as	the	automated	process	of	Xpert	takes	only	approximately	90	minutes	to	
completion.		This	is	crucial	to	ensure	early	and	adequate	treatment,	which	is	especially	
important	in	our	setting	with	one	of	the	highest	prevalence	rates	of	drug	resistant	disease	
worldwide.2	Without	Xpert,	affected	patients	may	wait	on	average	40	days	before	culture	
results	would	detect	drug	resistance.		Furthermore,	reliance	on	culture	with	delay	in	
diagnosis	and	treatment	may	also	result	in	serious	morbidity	such	as	joint	destruction	or	
paralysis	in	spinal	TB.21	Early	diagnosis	with	Xpert	can	therefore	influence	the	progression	of	
the	disease	and	the	implementation	of	appropriate	drug	therapy.			
For	these	reasons,	the	Xpert	assay	should	ideally	be	performed	onsite.		One	study	found	no	
difference	in	time	or	added	benefit	of	the	Xpert	compared	to	conventional	testing	methods	
when	Xpert	was	not	onsite.17	The	Xpert	assay	should	therefore	be	placed	in	hospitals	and	
clinics,	to	enable	easy	and	rapid	access.		However,	as	our	studies	have	shown,	Xpert	carried	
out	in	tertiary	care	hospitals	with	transport	of	specimens	to	a	central	testing	facility	was	still	
effective	for	rapid	diagnosis	in	suspected	musculoskeletal	TB.		
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Limitations	of	this	study	
One	of	the	disadvantages	of	PCR	testing	is	that	in	contrast	to	TB	culture,	PCR	testing	may	be	
positive	even	if	the	pathogens	are	non-viable.1	In	these	cases	active	TB	will	have	to	be	
confirmed	clinically,	by	culture	and	by	means	of	various	imaging	modalities.		However,	
unlike	pulmonary	TB,	this	is	not	an	important	issue	in	musculoskeletal	disease,	where	an	
initial	biopsy	is	usually	sufficient	to	make	the	diagnosis	and	where	re-biopsy	is	unlikely.	
A	further	limitation	is	that	Xpert	tests	only	rifampicin	resistance	therefore	mono-resistance	
for	isoniazid	cannot	be	detected,	nor	can	more	extensive	drug	resistance	be	evaluated.	
However,	current	treatment	guidelines	recommend	no	change	to	the	conventional	TB	
regimen	for	isoniazid	mono-resistance.		Thus,	in	cases	of	isoniazid	mono-resistance,	there	
will	be	no	impact	in	treatment	regime.18			Further,	next	generation	Xpert	tests	are	being	
developed	that	will	include	PCR	targets	for	INH	and	for	MDR	TB.		
Another	limitation	of	the	studies	is	that,	especially	for	our	spinal	TB	group,	they	were	
conducted	in	patients	with	advanced	disease	requiring	surgery	at	referral	hospitals.	The	
generalizability	of	these	results	to	patients	with	less	severe	disease	is	therefore	unclear;	
further	studies	of	patients	with	milder	forms	of	musculoskeletal	disease	and	in	peripheral	
hospitals	should	be	done.		
A	further	limitation	is	that	the	histological	diagnosis	was	made	by	a	single	pathologist.	
However,	clear	criteria	for	histopathological	diagnosis	were	used,	and	the	biopsies	were	
consistently	reviewed	in	a	standardized	way	by	an	experienced	pathologist.		The	use	of	a	
single	pathologist	may	conversely	strengthen	reliability	and	consistency	in	histological	
reporting.	The	accuracy	for	histology,	especially	for	our	paediatric	cohort,	might	also	not	be	
generalizable	to	a	setting	with	low	TB	burden,	as	our	pathologist	was	sensitised	to	the	
histological	diagnosis	of	TB	given	the	high	incidence	of	TB	in	this	geographical	area.	
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Nevertheless,	the	histological	signs	of	TB	are	clearly	delineated	and	should	be	recognizable	
by	any	trained	pathologist.				
A	further	limitation	is	the	use	of	different	methods	of	sample	collection,	guided	by	the	
anatomic	area	as	well	as	severity	of	the	disease,	which	could	have	potentially	resulted	in	
suboptimal	sample	collection.	More	aggressive	(open)	approaches	might	have	resulted	in	a	
standardized	way	of	surgical	sample	collection	but	may	have	resulted	in	unacceptable	
morbidity.		
Another	limitation	was	that	in	several	patients	the	HIV	status	was	unknown,	thus	reducing	
the	sample	size	for	comparison	of	HIV	positive	and	HIV	negative	adults.		However,	these	
numbers	are	similar	to	reports	published	by	the	WHO	on	the	African	region,	in	which	76%	of	
TB	patients	knew	their	HIV	status	in	2013.	The	relatively	small	number	of	HIV	positive	
children	limited	the	power	to	investigate	the	impact	of	HIV	on	the	accuracy	of	Xpert,	but	this	
reflects	a	strong	HIV	preventative	program	in	this	geographical	area,	reducing	the	incidence	
of	paediatric	HIV.			
We	also	did	not	record	previous	or	current	TB	treatment.	This	might	influence	the	accuracy	of	Xpert	or	increase	the	number	of	false	positive	culture	samples.	Furthermore,	a	recent	study43	has	shown	a	higher	false	positive	rate	in	these	cases	compared	with	new	cases.			
Another	limitation	of	our	paediatric	cohort	was	that	some	TB	culture	samples	were	
contaminated	or	were	not	processed	adequately;	the	exclusion	of	these	samples	might	have	
potentially	influenced	the	calculated	accuracy	of	Xpert.	However,	this	only	occurred	in	a	very	
small	number	of	specimens;	laboratory	contamination	of	around	5%	is	internationally	
regarded	as	acceptable	practice.	
	
	 60	
	
Future	research		
The	higher	rate	of	spinal	disease	amongst	our	adult	patients	with	confirmed	TB	(80%)	
compared	to	international	reports	(approximately	60%)	is	an	area	that	requires	further	
research.		Study	of	patients	with	less	severe	forms	of	musculoskeletal	disease	should	be	
undertaken	to	enable	greater	generalizability	of	these	results.			
The	question	why	Xpert	has	lower	accuracy	in	children,	HIV	negative	patients	and	
extraspinal	disease	remains	unanswered	and	larger	studies,	especially	for	childhood	
musculoskeletal	TB	are	needed.	
Investigation	and	comparison	of	the	yield	of	Xpert	from	less	invasive	samples	with	those	
from	musculoskeletal	biopsies,	such	as	superficial	lymph	nodes	or	samples	from	respiratory	
tract	are	needed.	Future	research	should	therefore	assess	the	sensitivity	of	Xpert	in	other	
samples	compared	to	musculoskeletal	samples.		
As	improved	next	generation	Xpert	tests	are	developed,	it	will	be	important	to	undertake	
further	research	to	evaluate	these	for	diagnosis	of	musculoskeletal	disease.		
	
Conclusions	and	Recommendations	
These	are	the	first	large	studies	on	the	accuracy	of	Xpert®	MTB/RIF	(Cepheid,	Sunnyvale,	CA)	
for	musculoskeletal	TB.	We	have	produced	evidence,	which	covers	a	large	research	gap	for	
diagnostic	accuracy	studies	in	musculoskeletal	TB,	especially	in	extraspinal	TB,	in	TB/HIV	co-
infections,	and	in	childhood	musculoskeletal	TB.	Based	on	these	results,	Xpert	should	be	
recommended	as	the	initial	test	as	it	is	more	sensitive	and	faster	than	culture.	The	National	
Health	Laboratory	System	in	the	Western	Cape	has	already	implemented	this.		All	rifampcin	
resistant	cases	were	correctly	diagnosed.	We	also	noted	a	rate	of	rifampicin	resistance	of	
approximately	5%,	which,	due	to	the	size	of	our	cohort	and	prospective	data	collection,	
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represents	rare	evidence	for	musculoskeletal	TB.		A	trend	towards	higher	sensitivity	in	spinal	
tissue	as	well	as	HIV	positive	patients	was	observed.		This	study	also	provides	evidence	that	
Xpert	has	a	lower	sensitivity	in	children	than	in	adults,	yet,	still	detects	more	cases	of	
paediatric	musculoskeletal	TB	and	is	faster	than	culture.	As	an	additional	finding	histology	
was	found	to	remain	a	useful	test	for	the	diagnosis	of	musculoskeletal	TB,	especially	in	
children,	and	should	be	used	alongside	Xpert	to	provide	the	highest	yield	possible	to	detect	
TB.												
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Dissemination	and	Publications	included	
The	dissemination	of	this	project	was	realized	by	means	of	podium	presentations	at	local,	
national,	and	international	meetings	and	congresses,	publications	in	international	
orthopaedic	journals	with	high	impact	factors,	and	by	influencing	regional	policy	changes.			
	
Influencing	Changes	in	Policy	of	testing	musculoskeletal	TB	
This	study,	amongst	others	has	proven	the	benefit	of	Xpert®	MTB/RIF	(Cepheid,	Sunnyvale,	
CA)	for	extrapulmonary	tissue.			Therefore,	after	being	implemented	nationally	for	selected	
extrapulmonary	specimens,	the	National	Health	Laboratory	System	(NHLS)	altered	the	
policies	regarding	testing	for	musculoskeletal	TB:	Xpert	will	now	be	the	first	test	for	
musculoskeletal	TB	in	the	Western	Cape.		The	algorithm	includes	a	reflex	culture	if	result	
shows	rifampicin	resistance	or	is	Xpert	is	negative,	but	NOT	if	result	indicates	rifampicin	
susceptible	TB.			
Dissemination	in	meetings	and	congresses	in	form	of	podium	presentations:	
1. Surgical	Research	Day,	2013,	University	of	Cape	Town	(Research	Prize)	
2. National	Meeting	of	South	African	Orthopaedic	Congress,	Sun	City,	2013	(GT	Du	Toit	
Prize	for	best	presentation)		
3. National	Meeting	of	South	African	Orthopaedic	Congress,	Cape	Town,	South	Africa,	
201475	
4. 21st	International	Meeting	on	Advanced	Spine	Techniques	(IMAST)	Valencia,	Spain	
July	16-19,	201476	 	 	
5. 13th	International	Meeting	of	the	Combined	Orthopaedic	Associations	(COMOC	-	
England,	Australia,	New	Zealand,	USA,	Canada	and	South	Africa),	Cape	Town	2016.		
6. SICOT	Orthopaedic	World	Congress.	Rome.	2016.	Accepted.	
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Publications	and	manuscripts	
Manuscript	1	(published)	
Xpert	MTB/RIF	for	spinal	tuberculosis:	an	accurate	and	rapid	diagnostic	test.		Bone	Joint	J.	
2014	Oct;96-B(10):1366-9.	doi:	10.1302/0301-620X.96B10.34048.	
Held	M,	Laubscher	M,	Zar	HJ,	Dunn	RN	
	
Manuscript	2	(submitted	to	Bone	&	Joint	Journal)	
Diagnostic	accuracy	of	Xpert	MTB/RIF	in	HIV	positive	and	HIV	negative	patients	with	
musculoskeletal	tuberculosis		
M	Held,	M	Laubscher,	L	Workman,	HJ	Zar,	R	Dunn	
	
Manuscript	3	(accepted	for	publication	in	the	Pediatric	Infectious	Disease	Journal)	
Diagnostic	accuracy	of	Xpert	MTB/RIF	in	tissue	samples	of	children	with	suspected	
musculoskeletal	TB		
M	Held,	M	Laubscher,	S	Mears,	S	Dix-Peek,	L	Workman,	HJ	Zar,	R	Dunn	
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The	Bone	&	Joint	Journal	(BJJ),	formerly	known	as	The	Journal	of	Bone	&	Joint	Surgery	
(British	Volume),	is	published	by	The	British	Editorial	Society	of	Bone	&	Joint	Surgery.		It	
ranks	amongst	the	worlds	top	10	orthopaedic	journals	with	an	impact	factor	of	2.801	
(August	2015).		
The	Pediatric	Infectious	Disease	Journal	is	published	by	the	European	Society	for	Paediatric	
Infectious	Diseases	and	has	an	impact	factor	of	2.7.	
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Contribution	of	Authors	
Introduction,	Methods	and	Conclusion	
I	have	written	the	introduction	and	conclusion,	which	was	revised	by	Prof	Dunn	and	Prof	Zar.		
Parts	of	the	methods	section	were	taken	out	of	the	included	manuscripts.		The	co-authors	of	
the	included	publications	reviewed	the	methods	sections	of	the	respective	publications.	
Lesley	Workman	reviewed	the	section	on	statistical	tests.	Dr	Bamford	and	N.	Beylis	provided	
insight	into	laboratory	tests	and	the	Xpert	assay	and	reviewed	this	section	of	our	methods.		
	
Chapter	3	and	4	
Authors:	M	Held,	M	Laubscher,	L	Workman,	HJ	Zar,	R	Dunn	
Chapter	3:	Xpert	Polymerase	Chain	Reaction	for	spinal	Tuberculosis	-	An	accurate	and	rapid	
diagnostic	test.	
Chapter	4:	Diagnostic	accuracy	of	Xpert	MTB/RIF	in	HIV	positive	and	HIV	negative	patients	
with	musculoskeletal	tuberculosis	
	
For	these	publications	I	developed	the	research	idea,	the	research	design	and	protocol.		Dr	
Laubscher	advised	on	the	research	design	and	protocol	and	assisted	with	the	setup	of	the	
study	sites.	I	collected	the	data	and	analyzed	the	data	under	the	supervision	of	Lesley	
Workman	and	Prof	Zar.		Dr	Bamford	and	N.	Beylis	provided	insight	into	laboratory	tests	and	
the	Xpert	assay	and	reviewed	this	section	of	our	methods.	Patients	were	recruited	and	
operated	on	by	Prof	Dunn	at	his	Orthopaedic	and	Spinal	Unit.		Prof	Dunn	is	also	the	principle	
investigator	of	this	study.		I	wrote	the	manuscript,	which	was	reviewed	by	Dr	Laubscher,	Prof	
Dunn	and	Prof	Zar.	Journal	submission	and	revision	of	this	publication	was	done	by	me	and	I	
am	the	corresponding	author.			
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Chapter	5:	Diagnostic	accuracy	of	Xpert	MTB/RIF	in	tissue	samples	of	children	with	
suspected	musculoskeletal	TB		
For	these	publications	I	developed	the	research	idea,	the	research	design	and	protocol.		Dr	
Laubscher	advised	on	the	research	design	and	protocol	and	assisted	with	the	setup	of	the	
study	sites.	Pediatric	patients	with	suspected	spinal	TB	were	operated	on	by	Prof	Dunn	at	his	
spinal	unit	at	Red	Cross	Hospital.		Prof	Dunn	is	also	the	Principle	Investigator	of	this	study.		
Dr	Dix-Peek	and	Dr	Mears	were	in	charge	of	the	recruitment	and	clinical	management	of	
pediatric	patients	at	Red	Cross	Children’s	Hospital.	I	collected	the	data	and	analyzed	the	data	
under	the	supervision	of	Lesley	Workman	and	Prof	Zar.		Dr	Bamford	and	N.	Beylis	provided	
insight	into	laboratory	tests	and	the	Xpert	assay	and	reviewed	this	section	of	our	methods.	I	
wrote	the	manuscript,	which	was	reviewed	by	Dr	Laubscher,	Dr	Dix-Peek,	Dr	Mears,	Prof	
Dunn	and	Prof	Zar.	Journal	submission	and	revision	of	this	publication	was	done	by	me	and	I	
am	the	corresponding	author.			
We	confirm	the	above:	
	 	 	 	 	 	 	 	 	 12.2.16	
				Dr	Michael	Held	–	primary	author	 	 	 	 	 	 							Date	
	 	 	 	 	 	 	 	 	 14.2.16	
				Prof	Robert	Dunn	–	Supervisor	 	 	 	 	 	 								Date	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 14.2.16	
								Date							
	
	
	
	
	 66	
Tables	
Chapter	1	
Table	1.	Current	evidence	on	diagnostic	accuracy	of	Xpert	in	musculoskeletal	samples.	
Chapter	2	
Table	1.	Clinical	and	radiological	red	flags	on	which	the	suspected	diagnosis	of	TB	was	made.	
Chapter	3	
Table	1.	Clinical	and	radiological	red	flags	on	which	the	suspected	diagnosis	of	TB	was	made.	
Table	2.	Baseline	characteristics	of	the	patient	cohort.	
Table	3.	Per	sample	accuracy	of	Xpert	MTB/RIF	for	detecting	TB.		PPV:	positive	predictive	
value.		
Chapter	4	
Table	1.		Characteristics	of	patient	cohort	and	biopsy	sites.	
Table	2.	Per-sample	comparison	of	the	accuracy	of	TB	culture	to	Xpert	with	the	reference	
standard	set	as	culture	or	histology	positive.	
Table	3.	Concordance	between	Xpert	and	culture	drug	susceptibility	testing	for	rifampicin	
resistance.	
Table	4.		Accuracy	of	Xpert	in	samples	comparing	HIV	positive	to	HIV	negative	patients	as	
well	as	spinal	to	extra	spinal	samples.	
Chapter	5	
Table	1.	Sites	of	biopsies.		
Table	2.		Characteristics	of	children	(per-patient).			
Table	3.	Per-sample	comparison	of	the	accuracy	of	TB	culture	to	Xpert	with	the	reference	
standard	set	as	TB	culture	positive	or	histology	positive	(23/109	samples).	
Table	4.	Time	to	availability	of	results	(in	days).	
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Table	5.	Concordance	between	Xpert	and	culture	drug	susceptibility	testing	for	rifampicin	
resistance.	
 
Figures	
Chapter	1	
	
Figure	1.	Estimated	TB	incidence	rates	in	2013.		
Figure	2.	Estimated	HIV	prevalence	in	new	and	relapse	TB	cases	in	2013.		
Figure	3.	Steps	using	the	Xpert	assay.			
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Information	sheet	for	patients	
 
INFORMATION	FOR	STUDY:		GeneXpert	as	diagnostic	tool	of	musculoskeletal	tuberculosis		
	
Institution	 Individuals	
Groote	Schuur	Hospital	 Prof.	Dunn,	M.	Held,	M.	Laubscher	
	
THE	 INFROMATION	 BELOW	WILL	 BE	 SUPPLIED	 TO	 ALL	 PATIENTS	 TAKING	 PART	 IN	 THIS	
STUDY.	
	
Your	symptoms	
You/your	child	have	been	admitted	and	examined	by	our	doctors.		Because	of	your	symptoms	
the	doctors	suspect	you	may	have	TB.		Depending	on	your	symptoms,	the	normal	standard	of	
care	for	TB	investigations	in	our	institution	usually	includes	a	chest	x-ray,	and	HIV	test,	blood	
tests	and	collection	of	tissue	to	look	for	TB.			
What	is	this	study	about?	
We	are	carrying	out	medical	research	to	find	better	ways	of	preventing	and	treating	TB	in	the	
future	 for	 everybody’s	 benefit.	 We	 want	 to	 find	 ways	 to	 diagnose	 TB	 quicker	 and	 more	
precisely.		To	achieve	this	we	would	like	to	assess	if	the	new	test	we	are	performing	on	all	of	
our	patients	with	suspected	TB	is	accurate	enough	to	make	this	possible	(GeneXpert).		This	
test	is	performed	on	all	tissues	we	collect	during	biopsies	of	our	patients,	regardless	of	their	
participation	in	this	study.		To	help	us	learn	more	we	are	asking	our	patients	to	allow	us	to	use	
the	data	we	are	collecting	from	their	samples	for	research	purposes.		There	will	be	no	personal	
data	included	in	the	database.	
What	will	it	involve	for	me/my	child?		
	
You/your	child	will	be	treated	no	different	to	anyone	who	does	not	take	part	 in	this	study.		
The	sample	we	collect	will	be	assessed	in	the	laboratory	in	the	same	way	as	if	you	would	not	
take	part	in	this	study.			
If	there	are	any	other	research	activities	that	our	staff	would	like	you	to	participate	in,	staff	
shall	explain	and	ask	your	permission	first.	
	
Are	there	any	risks	or	disadvantages	to	me	or	my	child	in	taking	part?	
	
You/your	child	will	have	exactly	the	same	risks	as	someone	-	with	your	condition	-	not	taking	
part	in	this	study.	
Are	there	any	benefits	to	me/my	child	of	taking	part?	
There	are	no	additional	benefits	for	you/your	child.	
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What	happens	if	I	refuse	to	participate?	
All	participation	in	research	is	voluntary.	You	are	free	to	decide	if	you	want	to	take	part.	If	you	
do	agree	you	can	change	your	mind	at	any	time	and	withdraw	from	the	research.	This	will	not	
affect	your/your	child’s	care	now	or	in	the	future.	
	
What	happens	to	the	samples?	
	
They	will	be	sent	to	the	national	health	laboratory.	 	Your	samples	will	be	treated	the	same	
way	as	samples	of	patients	who	are	not	participating	in	the	study.	
	
Who	will	have	access	to	information	about	me/my	child	in	this	research?	
	
The	doctors	who	are	also	 involved	 in	treating	your	medical	condition.	 	Any	additional	staff	
involved	 (Research	 assistance,	 statisticians)	 with	 the	 research	 project	 will	 see	 your	 data	
WITHOUT	your	personal	details.			
	
Who	has	allowed	this	research	to	take	place?	
	
Our	departmental	research	committee	and	the	local	ethics	committee	have	looked	carefully	
at	this	work	and	agreed	that	the	research	is	important,	that	it	will	be	conducted	properly	and	
participants’	safety	and	rights	have	been	respected.	
	
What	if	I	have	any	questions?	
You	may	ask	any	of	our	staff	questions	at	any	time.		The	principle	investigator	of	this	study	is:	
Prof.	Robert	Dunn,	Head:	Division	of	Orthopaedic	Surgery,	Spine	Deformity	Service	Red	Cross	
Children's	Hospital	
Secretaries:	University	of	Cape	Town,	Mrs	Priest,	tel.		021	404	5108		
	
If	you	want	to	ask	someone	independent	anything	about	this	research	please	contact	
If	you	have	any	questions,	concerns	or	complaints	about	this	research	study,	its	procedures,	
risks	and	benefits,	or	alternative	courses	of	treatment,	you	should	ask	the	Chairperson	of	the	
Human	Research	Ethics	Committee,	Prof	Blockman:	021	406	6492.	
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